



A service of the National Library of Medicine  
and the National Institutes of Health

My NCBI [?] [\[Sign In\]](#) [\[Register\]](#)

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search  for

Limits Preview/Index **History** Clipboard Details

About Entrez

Text Version

- Search History will be lost after eight hours of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.
- Click on query # to add to strategy

Entrez PubMed

Overview

Help | FAQ

Tutorials

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Search	Most Recent Queries	Time	Result
<a href="#">#12</a>	Search "Chang CH"[Author]	13:08:09	<u>1176</u>
<a href="#">#7</a>	Search Th2 type and EBV nuclear antigen	12:30:29	<u>3</u>
<a href="#">#6</a>	Search Th2 type immune response and EBV nuclear antigen	12:30:16	<u>0</u>
<a href="#">#5</a>	Search Th2 type immune response and EBNV-1	12:30:04	<u>0</u>
<a href="#">#4</a>	Search Th2 type immune response and EBNV-1 and SEL	12:29:58	<u>0</u>
<a href="#">#3</a>	Search Th2 type immune response and EBNV-1 and autoimmune	12:29:41	<u>0</u>
<a href="#">#2</a>	Search Th2 type immune response and EBV and autoimmune	12:29:12	<u>0</u>
<a href="#">#1</a>	Search Th2 type immune response and EBV	12:28:33	<u>9</u>

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 25 2006 06:31:58

=> d history

(FILE 'HOME' ENTERED AT 11:01:51 ON 01 AUG 2006)

FILE 'CAPLUS, BIOSIS' ENTERED AT 11:02:29 ON 01 AUG 2006

L1	9273	RIBAVIRIN
L2	170111	HEPATITIS
L3	5953	L1 AND L2
L4	3816972	TREATMENT
L5	3828	L3 AND L4
L6	4755	CORE (W) ANTIGEN
L7	4074	NS3
L8	50	L5 AND L6
L9	100	L5 AND L7
L10	200628	HIV
L11	819	L10 AND L1
L12	514	L11 AND L4
L13	3028344	PATIENT
L14	436	L13 AND L12
L15	97450	ENVELOPE
L16	1	L15 AND L14
L17	3580	L1 (S) L2
L18	1611	L4 (S) L17
L19	12	L6 (P) L18
L20	18	L8 (P) L18
L21	609	L10 (P) L1
L22	1	L21 (P) L15

FILE 'STNGUIDE' ENTERED AT 11:15:48 ON 01 AUG 2006

FILE 'CAPLUS' ENTERED AT 11:17:27 ON 01 AUG 2006

L23 73 L9

FILE 'STNGUIDE' ENTERED AT 11:20:09 ON 01 AUG 2006

## WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Tuesday, August 01, 2006

<b>Hide?</b>	<b>Set Name</b>	<b>Query</b>	<b>Hit Count</b>
<i>DB=PGPB,USPT,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>			
<input type="checkbox"/>	L7	L6 and ribavirin	32
<input type="checkbox"/>	L6	424/189.1.ICLS.	257
<input type="checkbox"/>	L5	L4 and ribavirin	16
<input type="checkbox"/>	L4	424/225.1.ICLS.	95
<input type="checkbox"/>	L3	L2 and ribavirin	6
<input type="checkbox"/>	L2	L1 and hepatitis	228
<input type="checkbox"/>	L1	424/93.1.ICLS.	969

END OF SEARCH HISTORY

## Hit List

[First Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

---

**Search Results - Record(s) 1 through 10 of 16 returned.**

---

☐ 1. Document ID: US 20050053625 A1

L5: Entry 1 of 16

File: PGPB

Mar 10, 2005

PGPUB-DOCUMENT-NUMBER: 20050053625

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050053625 A1

TITLE: Method of treating viral infections

PUBLICATION-DATE: March 10, 2005

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Block, Timothy M	Doylestown	PA	US
Mehta, Anand	Lansdale	PA	US
Dwek, Raymond	Oxford		GB

US-CL-CURRENT: [424/225.1](#); [424/227.1](#), [424/228.1](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 2. Document ID: US 20040141999 A1

L5: Entry 2 of 16

File: PGPB

Jul 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040141999

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040141999 A1

TITLE: Antiviral and antiretroviral radioimmunomedicaments based on (alpha)-emitters and (beta)-emitters

PUBLICATION-DATE: July 22, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Bergter, Wolfgang	Hannover		DE

US-CL-CURRENT: [424/192.1](#); [424/1.11](#), [424/141.1](#), [424/208.1](#), [424/225.1](#), [424/227.1](#), [424/228.1](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 3. Document ID: US 20030170273 A1



L5: Entry 3 of 16

File: PGPB

Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030170273  
PGPUB-FILING-TYPE: new  
DOCUMENT-IDENTIFIER: US 20030170273 A1

TITLE: Adjuvant compositions

PUBLICATION-DATE: September 11, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
O'Hagan, Derek	Berkeley	CA	US
Valiante, Nicholas	Fremont	CA	US

US-CL-CURRENT: 424/225.1; 424/130.1, 424/199.1, 435/6, 514/44

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-----

☐ 4. Document ID: US 20030157132 A1

L5: Entry 4 of 16

File: PGPB

Aug 21, 2003

PGPUB-DOCUMENT-NUMBER: 20030157132  
PGPUB-FILING-TYPE: new  
DOCUMENT-IDENTIFIER: US 20030157132 A1

TITLE: Remedies for hepatitis c

PUBLICATION-DATE: August 21, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Itami, Seima	Tokyo		JP
Shibui, Tatsurou	Tokyo		JP
Seki, Makoto	Tokyo		JP
Yotsumoto, Yoshihisa	Tokyo		JP
Matsuura, Yoshiharu	Osaka		JP
Miyamura, Tatsuo	Tokyo		JP

US-CL-CURRENT: 424/225.1; 424/186.1, 424/204.1, 435/325, 435/91.1, 435/91.33, 530/300

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-----

☐ 5. Document ID: US 20030148348 A1

L5: Entry 5 of 16

File: PGPB

Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030148348  
PGPUB-FILING-TYPE: new  
DOCUMENT-IDENTIFIER: US 20030148348 A1

TITLE: Self-replicating RNA molecule from hepatitis C virus

PUBLICATION-DATE: August 7, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kukolj, George	Laval		CA
Pause, Arnim	Laval		CA

US-CL-CURRENT: 435/6; 424/225.1, 435/69.1, 435/91.1, 435/91.33

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-----

☐ 6. Document ID: US 20030138458 A1

L5: Entry 6 of 16

File: PGPB

Jul 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030138458

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030138458 A1

TITLE: HCV E1E2 vaccine compositions

PUBLICATION-DATE: July 24, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Houghton, Michael	Danville	CA	US
Coates, Stephen R.	Orinda	CA	US
O'Hagan, Derek	Berkeley	CA	US

US-CL-CURRENT: 424/225.1; 424/204.1, 424/278.1, 435/6, 514/44

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-----

☐ 7. Document ID: US 20030049277 A1

L5: Entry 7 of 16

File: PGPB

Mar 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030049277

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030049277 A1

TITLE: Composition for treatment of and method of monitoring hepatitis C virus using interferon-TAU

PUBLICATION-DATE: March 13, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Sokawa, Yoshihiro	Kyoto	CA	JP
Liu, Chih-Ping	San Francisco		US

US-CL-CURRENT: 424/228.1; 424/225.1, 424/450, 435/5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 8. Document ID: US 20030013118 A1

L5: Entry 8 of 16

File: PGPB

Jan 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030013118

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030013118 A1

TITLE: METHODS OF DETERMINING RESISTANCE TO TREATMENT FOR HEPATITIS C VIRUS

PUBLICATION-DATE: January 16, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
EDGE, ALBERT	CAMBRIDGE	MA	US
AFDHAL, NEZAM H.	CHARLESTOWN	MA	US

US-CL-CURRENT: 435/7.1; 424/225.1, 435/5, 435/69.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 9. Document ID: US 20020155434 A1

L5: Entry 9 of 16

File: PGPB

Oct 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020155434

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020155434 A1

TITLE: Hepatitis B virus treatment

PUBLICATION-DATE: October 24, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Mizzen, Lee A.	Victoria	PA	CA
Siegel, Marvin	Blue Bell		US
Liu, Hongwei	Victoria		CA

US-CL-CURRENT: 435/5; 424/192.1, 424/204.1, 424/225.1, 424/227.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 10. Document ID: US 20020155133 A1

L5: Entry 10 of 16

File: PGPB

Oct 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020155133

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020155133 A1

TITLE: Hepatitis C virus constructs characterized by high efficiency replication

PUBLICATION-DATE: October 24, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Bichko, Vadim	Belmont	MA	US

US-CL-CURRENT: [424/225.1](#); [424/204.1](#), [424/93.2](#), [435/235.1](#), [435/456](#), [435/91.1](#), [536/23.1](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-----

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Terms

Documents

L4 and ribavirin

16

Display Format:

[Change Format](#)[Previous Page](#)[Next Page](#)[Go to Doc#](#)

## Hit List

[First Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

---

**Search Results - Record(s) 11 through 16 of 16 returned.**

---

☐ 11. Document ID: US 20020155124 A1

L5: Entry 11 of 16

File: PGPB

Oct 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020155124

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020155124 A1

TITLE: Vaccines containing ribavirin and methods of use thereof

PUBLICATION-DATE: October 24, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Sallberg, Matti	Alvsjo		SE
Hultgren, Catharina	Stockholm		SE

US-CL-CURRENT: 424/189.1; 424/204.1, 424/225.1, 424/226.1, 424/227.1, 435/5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-----

☐ 12. Document ID: US 20020136740 A1

L5: Entry 12 of 16

File: PGPB

Sep 26, 2002

PGPUB-DOCUMENT-NUMBER: 20020136740

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020136740 A1

TITLE: Vaccines containing ribavirin and methods of use thereof

PUBLICATION-DATE: September 26, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Sallberg, Matti	Alvsjo		SE
Hultgren, Catharina	Stockholm		SE

US-CL-CURRENT: 424/225.1; 424/204.1, 424/227.1, 424/93.2, 435/5, 435/91.1, 435/91.33, 514/43, 514/44

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-----

☐ 13. Document ID: US 6828139 B2

L5: Entry 13 of 16

File: USPT

Dec 7, 2004

US-PAT-NO: 6828139

DOCUMENT-IDENTIFIER: US 6828139 B2

TITLE: Production of replicative hepatitis C virus

DATE-ISSUED: December 7, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schmidt; Emmett Vance	Andover	MA		
Chung; Raymond Taeyong	Boston	MA		

US-CL-CURRENT: 435/235.1; 424/225.1, 424/228.1, 435/320.1, 435/325, 435/41, 435/42, 435/440, 435/5, 435/6, 435/91.1, 435/91.21, 435/91.31, 536/24.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Legal Events	Continuations	Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--------------	---------------	--------	------	-----------	-----

☐ 14. Document ID: US 6680059 B2

L5: Entry 14 of 16

File: USPT

Jan 20, 2004

US-PAT-NO: 6680059

DOCUMENT-IDENTIFIER: US 6680059 B2

TITLE: Vaccines containing ribavirin and methods of use thereof

DATE-ISSUED: January 20, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sallberg; Matti	Alvsjo			SE
Hultgren; Catharina	Stockholm			SE

US-CL-CURRENT: 424/225.1; 424/189.1, 424/204.1, 424/227.1, 424/228.1, 424/93.2, 435/5, 435/91.2, 435/91.33, 514/2, 514/23, 514/27, 514/43, 514/44, 514/46, 514/49, 977/802

Full	Title	Citation	Front	Review	Classification	Date	Reference	Legal Events	Continuations	Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--------------	---------------	--------	------	-----------	-----

☐ 15. Document ID: US 6524589 B1

L5: Entry 15 of 16

File: USPT

Feb 25, 2003

US-PAT-NO: 6524589

DOCUMENT-IDENTIFIER: US 6524589 B1

TITLE: Compositions of hepatitis C virus NS3/NS4A complex and methods for crystallizing same

DATE-ISSUED: February 25, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Reichert; Paul	Montville	NJ		

Prosise; Winifred W.	Ramsey	NJ
Taremi; Shahriar Shane	Upper Montclair	NJ
Yao; Nanhua	Edison	NJ
Weber; Patricia C.	Yardley	PA

US-CL-CURRENT: [424/228.1](#); [424/184.1](#), [424/225.1](#), [514/12](#), [514/13](#), [514/2](#), [702/19](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	SPRINGER	DOCUMENT	Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	----------	----------	--------	------	-----------	-----

☒ 16. Document ID: US 6447994 B1

L5: Entry 16 of 16

File: USPT

Sep 10, 2002

US-PAT-NO: 6447994

DOCUMENT-IDENTIFIER: US 6447994 B1

TITLE: Production of replicative hepatitis C virus

DATE-ISSUED: September 10, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schmidt; Emmett Vance	Andover	MA		
Chung; Raymond Taeyong	Boston	MA		

US-CL-CURRENT: [435/5](#); [424/225.1](#), [424/228.1](#), [435/366](#), [435/465](#), [435/6](#), [435/7.21](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	SPRINGER	DOCUMENT	Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	----------	----------	--------	------	-----------	-----

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Terms

Documents

L4 and ribavirin

16

Display Format:  [Change Format](#)[Previous Page](#)[Next Page](#)[Go to Doc#](#)

## Hit List

[First Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

### Search Results - Record(s) 1 through 10 of 16 returned.

☐ 1. Document ID: US 20050053625 A1

L5: Entry 1 of 16

File: PGPB

Mar 10, 2005

PGPUB-DOCUMENT-NUMBER: 20050053625

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050053625 A1

TITLE: Method of treating viral infections

PUBLICATION-DATE: March 10, 2005

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Block, Timothy M	Doylestown	PA	US
Mehta, Anand	Lansdale	PA	US
Dwek, Raymond	Oxford		GB

US-CL-CURRENT: [424/225.1](#); [424/227.1](#), [424/228.1](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-----

☐ 2. Document ID: US 20040141999 A1

L5: Entry 2 of 16

File: PGPB

Jul 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040141999

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040141999 A1

TITLE: Antiviral and antiretroviral radioimmunomedicaments based on (alpha)-emitters and (beta)-emitters

PUBLICATION-DATE: July 22, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Bergter, Wolfgang	Hannover		DE

US-CL-CURRENT: [424/192.1](#); [424/1.11](#), [424/141.1](#), [424/208.1](#), [424/225.1](#), [424/227.1](#), [424/228.1](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-----

☐ 3. Document ID: US 20030170273 A1



L5: Entry 3 of 16

File: PGPB

Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030170273  
PGPUB-FILING-TYPE: new  
DOCUMENT-IDENTIFIER: US 20030170273 A1

TITLE: Adjuvant compositions

PUBLICATION-DATE: September 11, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
O'Hagan, Derek	Berkeley	CA	US
Valiante, Nicholas	Fremont	CA	US

US-CL-CURRENT: 424/225.1; 424/130.1, 424/199.1, 435/6, 514/44

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-----

☐ 4. Document ID: US 20030157132 A1

L5: Entry 4 of 16

File: PGPB

Aug 21, 2003

PGPUB-DOCUMENT-NUMBER: 20030157132  
PGPUB-FILING-TYPE: new  
DOCUMENT-IDENTIFIER: US 20030157132 A1

TITLE: Remedies for hepatitis c

PUBLICATION-DATE: August 21, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Itami, Seima	Tokyo		JP
Shibui, Tatsurou	Tokyo		JP
Seki, Makoto	Tokyo		JP
Yotsumoto, Yoshihisa	Tokyo		JP
Matsuura, Yoshiharu	Osaka		JP
Miyamura, Tatsuo	Tokyo		JP

US-CL-CURRENT: 424/225.1; 424/186.1, 424/204.1, 435/325, 435/91.1, 435/91.33, 530/300

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-----

☐ 5. Document ID: US 20030148348 A1

L5: Entry 5 of 16

File: PGPB

Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030148348  
PGPUB-FILING-TYPE: new  
DOCUMENT-IDENTIFIER: US 20030148348 A1

TITLE: Self-replicating RNA molecule from hepatitis C virus

PUBLICATION-DATE: August 7, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kukolj, George	Laval		CA
Pause, Arnim	Laval		CA

US-CL-CURRENT: 435/6; 424/225.1, 435/69.1, 435/91.1, 435/91.33

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-----

☐ 6. Document ID: US 20030138458 A1

L5: Entry 6 of 16

File: PGPB

Jul 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030138458

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030138458 A1

TITLE: HCV E1E2 vaccine compositions

PUBLICATION-DATE: July 24, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Houghton, Michael	Danville	CA	US
Coates, Stephen R.	Orinda	CA	US
O'Hagan, Derek	Berkeley	CA	US

US-CL-CURRENT: 424/225.1; 424/204.1, 424/278.1, 435/6, 514/44

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-----

☐ 7. Document ID: US 20030049277 A1

L5: Entry 7 of 16

File: PGPB

Mar 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030049277

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030049277 A1

TITLE: Composition for treatment of and method of monitoring hepatitis C virus using interferon-TAU

PUBLICATION-DATE: March 13, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Sokawa, Yoshihiro	Kyoto	CA	JP
Liu, Chih-Ping	San Francisco		US

US-CL-CURRENT: 424/228.1; 424/225.1, 424/450, 435/5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 8. Document ID: US 20030013118 A1

L5: Entry 8 of 16

File: PGPB

Jan 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030013118

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030013118 A1

TITLE: METHODS OF DETERMINING RESISTANCE TO TREATMENT FOR HEPATITIS C VIRUS

PUBLICATION-DATE: January 16, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
EDGE, ALBERT	CAMBRIDGE	MA	US
AFDHAL, NEZAM H.	CHARLESTOWN	MA	US

US-CL-CURRENT: 435/7.1; 424/225.1, 435/5, 435/69.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 9. Document ID: US 20020155434 A1

L5: Entry 9 of 16

File: PGPB

Oct 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020155434

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020155434 A1

TITLE: Hepatitis B virus treatment

PUBLICATION-DATE: October 24, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Mizzen, Lee A.	Victoria	PA	CA
Siegel, Marvin	Blue Bell		US
Liu, Hongwei	Victoria		CA

US-CL-CURRENT: 435/5; 424/192.1, 424/204.1, 424/225.1, 424/227.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 10. Document ID: US 20020155133 A1

L5: Entry 10 of 16

File: PGPB

Oct 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020155133

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020155133 A1

TITLE: Hepatitis C virus constructs characterized by high efficiency replication

PUBLICATION-DATE: October 24, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Bichko, Vadim	Belmont	MA	US

US-CL-CURRENT: [424/225.1](#); [424/204.1](#), [424/93.2](#), [435/235.1](#), [435/456](#), [435/91.1](#), [536/23.1](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-----

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Terms

Documents

L4 and ribavirin

16

Display Format:

[Change Format](#)[Previous Page](#)[Next Page](#)[Go to Doc#](#)

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1648BQL

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 4 APR 04 STN AnaVist \$500 visualization usage credit offered  
NEWS 5 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records  
NEWS 6 MAY 11 KOREAPAT updates resume  
NEWS 7 MAY 19 Derwent World Patents Index to be reloaded and enhanced  
NEWS 8 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAPLUS and  
USPATFULL/USPAT2  
NEWS 9 MAY 30 The F-Term thesaurus is now available in CA/CAPLUS  
NEWS 10 JUN 02 The first reclassification of IPC codes now complete in  
INPADOC  
NEWS 11 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and  
and display fields  
NEWS 12 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL  
NEWS 13 JUL 11 CHEMSAFE reloaded and enhanced  
NEWS 14 JUL 14 FSTA enhanced with Japanese patents  
NEWS 15 JUL 19 Coverage of Research Disclosure reinstated in DWPI

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b,  
CURRENT

MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 11:01:51 ON 01 AUG 2006

=> file caplus biosis

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		0.21	0.21

FILE 'CAPLUS' ENTERED AT 11:02:29 ON 01 AUG 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 11:02:29 ON 01 AUG 2006

Copyright (c) 2006 The Thomson Corporation

=> ribavirin

L1 9273 RIBAVIRIN

=> hepatitis

L2 170111 HEPATITIS

=> L1 and l2

L3 5953 L1 AND L2

=> treatment

L4 3816972 TREATMENT

=> L3 and l4

L5 3828 L3 AND L4

=> core (w) antigen

L6 4755 CORE (W) ANTIGEN

=> NS3

L7 4074 NS3

=> L5 and L6

L8 50 L5 AND L6

=> L5 and L7

L9 100 L5 AND L7

=> HIV

L10 200628 HIV

=> L10 and L1

L11 819 L10 AND L1

=> L11 and L4

L12 514 L11 AND L4

=> patient

L13 3028344 PATIENT

=> L13 and L12

L14 436 L13 AND L12

=> envelope

L15 97450 ENVELOPE

=> L15 and L14

L16 1 L15 AND L14

=> D L16 IBIB ABS

L16 ANSWER 1 OF 1 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN

ACCESSION NUMBER: 2002:626918 BIOSIS

DOCUMENT NUMBER: PREV200200626918

TITLE: Prevalence of occult hepatitis B in a large multinational  
trial of the treatment of HCV with peginterferon  
alfa-2a (40KD) (Pegasys(R)) in patients  
coinfectd with HIV.

AUTHOR(S): Rodriquez-Torres, Maribel [Reprint author];  
Gonzalez-Garcia, Juan; Mendes-Correa, Maria; Katlama,  
Christine; Nelson, Mark; Cooper, D.; Staszewski, Schlomo;  
Carosi, Giampiero; Smaill, Fiona; Brau, Norbert

CORPORATE SOURCE: Fundacion Gastroenterologia de Diego, Santurce, Puerto Rico

SOURCE: Hepatology, (October, 2002) Vol. 36, No. 4 Part 2, pp.  
578A. print.

Meeting Info.: 53rd Annual Meeting on the Liver. BOSTON,  
MA, USA. November 01-05, 2002.

CODEN: HPTLD9. ISSN: 0270-9139.  
DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
LANGUAGE: English  
ENTRY DATE: Entered STN: 12 Dec 2002  
Last Updated on STN: 12 Dec 2002

=> L1 (s) L2  
L17 3580 L1 (S) L2

=> L4 (s) L17  
L18 1611 L4 (S) L17

=> L6 (p) L18  
L19 12 L6 (P) L18

=> L8 (p) L18  
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
FIELD CODE - 'AND' OPERATOR ASSUMED 'L22 (P) L52'  
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
FIELD CODE - 'AND' OPERATOR ASSUMED 'L23 (P) L53'  
L20 18 L8 (P) L18

=> L10 (p) L1  
L21 609 L10 (P) L1

=> L21 (p) L15  
L22 1 L21 (P) L15

=> D L22 IBIB

L22 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2005:1068577 CAPLUS  
DOCUMENT NUMBER: 144:64852

TITLE: Comparison of amplification enzymes for hepatitis C  
virus quasispecies analysis

AUTHOR(S): Polyak, Stephen J.; Sullivan, Daniel G.; Austin,  
Michael A.; Dai, James Y.; Shuhart, Margaret C.;  
Lindsay, Karen L.; Bonkovsky, Herbert L.; Di  
Bisceglie, Adrian M.; Lee, William M.; Morishima,  
Chihiro; Gretch, David R.

CORPORATE SOURCE: The HALT-C Trial Group, Virology Division, Department  
of Laboratory Medicine, University of Washington,  
Seattle, WA, USA

SOURCE: Virology Journal (2005), 2, No pp. given



CODEN: VJIOA4; ISSN: 1743-422X  
URL: <http://www.virologyj.com/content/pdf/1743-422X-2-41.pdf>

PUBLISHER: BioMed Central Ltd.  
DOCUMENT TYPE: Journal; (online computer file)  
LANGUAGE: English  
REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES  
AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> D L19 IBIB ABS 1-12

L19 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:549206 CAPLUS

DOCUMENT NUMBER: 145:58344

TITLE: How to use viral genomic analysis in clinical practice  
chronic hepatitis B and C

AUTHOR(S): Izumi, Namiki

CORPORATE SOURCE: Dep. Gastroenterol. Hepatol., Musashino Red Cross  
Hospital, Musashino, 180-8610, Japan

SOURCE: Rinsho Byori (2006), 54(4), 395-399

CODEN: RBYOAI; ISSN: 0047-1860

PUBLISHER: Nippon Rinsho Kensa Igakkai

DOCUMENT TYPE: Journal; General Review

LANGUAGE: Japanese

AB A review. Viral genomic anal. has been developed recently, and is utilized in clin. practice. The genotype of HB virus has the most important clin. implication, and in Japan, genotype C shows worse prognosis than genotype B. Basic core promoter (BCP) mutation is assocd. with hepatic fibrosis, and HBe antigen seronegativity is frequently obsd. after lamivudine administration than wild type. Polymerase domain B mutation was shown to be assocd. with lamivudine resistance concomitantly with domain C mutation. In the treatment of chronic hepatitis C genotype 1b infection, peginterferon and ribavirin combination therapy was introduced, and this combination therapy has been shown to induce 50% sustained virol. response (SVR). To predict the virol. response to combination therapy, monitoring viral decline provides the most important information. Real-time PCR is expensive, highly sensitive core antigen quantitation is valuable in clin. practice. When patients treated by combination therapy achieve a 2 log drop in HCV antigen until twelve weeks they are estd. to have obtained 75% SVR by monitoring the amt. of serum core antigen.

L19 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:137679 CAPLUS  
DOCUMENT NUMBER: 145:61030  
TITLE: Fundamental evaluation and clinical efficacy of high sensitive HCV-core antigen measurement assay  
AUTHOR(S): Fukuda, Mika; Yatsuhashi, Hiroshi; Yano, Koji; Oguro, Manabu; Ishibashi, Ohmi; Takezaki, Eiichi; Hirooka, Taizo; Sakai, Hironori; Muro, Toyokichi; Masaki, Naohiko; Komatsu, Tatsuji; Morimoto, Hideo; Saoshiro, Jobu; Masumoto, Akihide; Sodeyama, Takeshi; Shimada, Masaaki; Santo, Takehiro; Watanabe, Yukio; Chida, Nobuyuki; Ohara, Yukio; Yamashita, Haruhiro; Harada, Eiji  
CORPORATE SOURCE: Clinical Research Center, Nagasaki Medical Center, Japan  
SOURCE: Igaku to Yakugaku (2005), 54(5), 677-682  
CODEN: IGYAEI; ISSN: 0389-3898  
PUBLISHER: Shizen Kagakusha  
DOCUMENT TYPE: Journal  
LANGUAGE: Japanese  
AB The aim of this study is to evaluate clin. efficacy of a highly sensitive hepatitis C virus (HCV) core antigen-detecting assay in patients with chronic hepatitis C after interferon/ribavirin therapy. The test demonstrated good reproducibility and reliability. After interferon/ribavirin therapy, non-responsive cases showed significant higher core antigen than responsive cases. The study showed that the therapeutic efficacy is reduced when HCV core antigen vol. is less than 1000 fmol/L. The test is useful in detecting HCV core antigen, which is a predictive factor for therapeutic efficacy of interferon/ribavirin treatment of chronic hepatitis C.

L19 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:526344 CAPLUS  
DOCUMENT NUMBER: 141:241642  
TITLE: The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment  
AUTHOR(S): Pradat, Pierre; Maynard, Marianne; Buti, Maria; Berthillon, Pascale; Picchio, Gaston; Tillmann, Hans L.; Wiegand, Johannes; Voirin, Nicolas; Manns, Michael P.; Esteban, Juan-Ignacio; Martinot, Michele; Marcellin, Patrick; Trepo, Christian  
CORPORATE SOURCE: Department of Hepatology, Hotel-Dieu, Lyon, Fr.  
SOURCE: Journal of Medical Virology (2004), 73(3), 392-396  
CODEN: JMVIDB; ISSN: 0146-6615

PUBLISHER: Wiley-Liss, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A new quant. marker of HCV viremia based on the detection of the core antigen of the virus has recently become com. available in Europe. The usefulness of this test was examd. for the management of patients treated with pegylated interferon/ribavirin. One hundred twenty-eight pegylated interferon/ribavirin treated patients were studied. Serum samples were available at baseline, week 4, and week 12 time-points, resp. Core antigen was quantified using the trak-C assay (Ortho Clin. Diagnostics, Raritan, NJ). For all genotypes at week 4, the pos. and neg. predictive values of HCV core antigen were 81.4 and 92.9%, resp., while at week 12 they were 67.9 and 100%, resp. These predictive values varied substantially according to viral genotype. Among patients with a neg. core antigen level (<1.5 pg/mL) at week 12, only 33% of those who were pos. at week 4 achieved a sustained virol. response whereas 85% of those who were already neg. did. The core antigen assay may be used at week 4 and week 12 to distinguish patients who will achieve a sustained virol. response from those who will relapse/breakthrough. This assay is a new reliable alternative for early prediction of virol. non-response in patients treated with pegylated interferon/ribavirin.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:682658 CAPLUS

DOCUMENT NUMBER: 138:23465

TITLE: CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens in patients coinfectd with HCV and human immunodeficiency virus who responded to anti-HCV treatment

AUTHOR(S): Legrand, Elisabeth; Neau, Didier; Galperine, Tatiana; Trimoulet, Pascale; Moreau, Jean-Francois; Pitard, Vincent; Lacut, Jean-Yves; Ragnaud, Jean-Marie; Dupon, Michel; Le Bail, Brigitte; Bernard, Noelle; Schvoerer, Evelyne; Houghton, Michael; Fleury, Herve; Lafon, Marie-Edith

CORPORATE SOURCE: Virology Laboratory, Bordeaux 2 University, Fr.

SOURCE: Journal of Infectious Diseases (2002), 186(3), 302-311

CODEN: JIDIAQ; ISSN: 0022-1899

PUBLISHER: University of Chicago Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens were evaluated before and during an anti-HCV regimen

(interferon-.alpha.2a and ribavirin) in 36 patients coinfectd with HCV and human immunodeficiency virus (HIV), to det. whether immune responses against HCV antigens are present in such patients, whether these responses are modified by anti-HCV treatment, and whether they are correlated with treatment efficacy. The CD4 responses against HCV antigens (primarily core antigens) detected at study entry in one-half of the patients did not correlate with anti-HCV treatment efficacy. Of 36 patients, 8 had patterns of persistent immune response to infection by genotypes 3 or 4 that were significantly correlated with sustained virol. response. Persistent immunol. reactivity and sustained virol. response coexisted only in patients infected with genotype 3. These findings suggest that HCV genotype may influence specific immune response, which, in turn, is implicated in virol. control.

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:813914 CAPLUS

DOCUMENT NUMBER: 137:27954

TITLE: Ribavirin Enhances Interferon-.gamma. Levels in Patients with Chronic Hepatitis C Treated with Interferon-.alpha.

AUTHOR(S): Fang, Shih-Hua; Lai, Ming-Yang; Hwang, Lih-Hwa; Yang, Pei-Ming; Chen, Pei-Jer; Chiang, Bor-Luen; Chen, Ding-Shinn

CORPORATE SOURCE: Graduate Institute of Microbiology, National Taiwan University, Taipei, Taiwan

SOURCE: Journal of Biomedical Science (Basel, Switzerland) (2001), 8(6), 484-491

CODEN: JBCIEA; ISSN: 1021-7770

PUBLISHER: S. Karger AG

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Some patients with chronic hepatitis C respond to interferon (IFN)-.alpha. treatment, and the efficiency can be improved by combining it with ribavirin. The mechanism of this improvement is unknown. To investigate the effects of these two regimens on the immune responses in 51 patients with chronic hepatitis C, the authors examd. the hepatitis C core antigen-specific proliferative response and cytokine prodn. profiles, natural killer (NK) cell cytotoxicity, and cytotoxic T cell function during treatment. The results are as follows: (1) both viral clearance and biochem. normalization occurred more frequently in patients receiving combination therapy; (2) the function of NK cells increased after treatment in the responders of both groups; (3) the level of IFN-.gamma. produced by

hepatitis C core antigen-stimulated peripheral blood mononuclear cells was higher in patients receiving combination therapy, esp. in responders; (4) the core antigen-specific proliferative response decreased after treatment, and (5) in addn., the core-specific cytotoxic T cell activities of 5 responder patients also increased after therapy. Thus, enhancement of immune responses, esp. those related to type-1 T helper cell activity, may contribute to better efficacy in combining ribavirin with IFN-.alpha. for treatment of chronic hepatitis C.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 6 OF 12 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN

ACCESSION NUMBER: 2004:325700 BIOSIS

DOCUMENT NUMBER: PREV200400327000

TITLE: The predictive value of core antigen  
testing for the management of hepatitis C  
patients receiving pegylated interferon/ribavirin  
treatment.

AUTHOR(S): Pradat, Pierre [Reprint Author]; Maynard, Marianne; Buti,  
Maria; Berthillon, Pascale; Picchio, Gaston; Tillmann, Hans  
L.; Wiegand, Johannes; Voirin, Nicolas; Manns, Michael P.;  
Esteban, Juan-Ignacio; Martinot, Michele; Marcellin,  
Patrick; Trepo, Christian

CORPORATE SOURCE: Dept Hepatol, Hop Hotel Dieu, 1,Pl Hop, F-69288, Lyon, 02,  
France  
pradat@univ-lyon1.fr

SOURCE: Journal of Medical Virology, (July 2004) Vol. 73, No. 3,  
pp. 392-396. print.  
CODEN: JMVIDB. ISSN: 0146-6615.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 29 Jul 2004  
Last Updated on STN: 29 Jul 2004

AB A new quantitative marker of HCV viremia based on the detection of the core antigen of the virus has recently become commercially available in Europe. The usefulness of this test was examined for the management of patients treated with pegylated interferon/ribavirin. One hundred twenty-eight pegylated interferon/ribavirin treated patients were studied. Serum samples were available at baseline, week 4 and week 12 time-points, respectively. Core antigen was quantified using the trak-C assay (Ortho Clinical Diagnostics, Raritan, NJ). For all genotypes at week 4, the positive and negative predictive values of HCV core antigen were 81.4 and 92.9%, respectively, while at week 12 they were 67.9 and 100%,

respectively. These predictive values varied substantially according to viral genotype. Among patients with a negative core antigen level (<1.5 pg/ml) at week 12, only 33% of those who were positive at week 4 achieved a sustained virological response whereas 85% of those who were already negative did ( $P < 0.001$ ). The core antigen assay may be used at week 4 and week 12 to distinguish patients who will achieve a sustained virological response from those who will relapse/breakthrough. This assay is a new reliable alternative for early prediction of virological non-response in patients treated with pegylated interferon/ribavirin.  
Copyright 2004 Wiley-Liss, Inc.

L19 ANSWER 7 OF 12 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2004:123681 BIOSIS

DOCUMENT NUMBER: PREV200400116810

TITLE: Pharmacodynamics and pharmacokinetics of hepatitis C virus (HCV) and pegylated interferon-alfa2b in human immunodeficiency virus (HIV)/HCV co-infected patients.

AUTHOR(S): Golia, Preeti [Reprint Author]; Powers, Kimberly; Dorante, Gary [Reprint Author]; Cunningham-Rundles, Susanna [Reprint Author]; Ribeiro, Ruy; Shata, Mohammed T.; Perelson, Alan S.; Talal, Andrew H. [Reprint Author]

CORPORATE SOURCE: Weill Medical College of Cornell University, New York, NY, USA

SOURCE: Hepatology, (October 2003) Vol. 38, No. 4 Suppl. 1, pp. 345A. print.

Meeting Info.: 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA. October 24-28, 2003. American Association for the Study of Liver Diseases.

ISSN: 0270-9139 (ISSN print).

DOCUMENT TYPE: Conference; (Meeting)

Conference; (Meeting Poster)

Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 3 Mar 2004

Last Updated on STN: 3 Mar 2004

AB Background: Approximately one half of hepatitis C virus (HCV) infected patients will fail to respond to current treatment regimens, pegylated interferon alfa and ribavirin. Modeling of HCV RNA decay in response to antiviral therapy can provide insight into viral and host determinants of viral response. Aims: Pharmacokinetic, pharmacodynamic, and immunologic outcomes were evaluated on 24 co-infected patients: 1) To evaluate the relationship between HCV RNA decay and PEG-IFN alfa2b serum concentrations in HIV/HCV co-infected patients and 2) to evaluate association between HCV-specific immune responses and

virologic outcome. Methods: 24 co-infected, therapy-naive patients were treated with PEG-IFN alfa2b 1.5mg/kg/wk and RBV 13+2 mg/kg/day. Serum was obtained for HCV RNA, HIV-1 RNA and serum PEG-IFN alfa2b levels at baseline, after the first dose (6, 12, 24 hours) and on days 2, 3, 5, 6; after the second dose (6, 12, 24 hours) and on days 8, 9; and after the third dose on days 14, 15, and 16. Peripheral blood mononuclear cells were obtained at baseline, weekly for the first month, and monthly thereafter. HCV and HIV-1 RNA levels were determined by reverse-transcriptase polymerase chain reaction and PEG-IFN alfa2b levels were measured by ELISA. CD4+ cell proliferative responses to HCV antigens (core, NS3, NS4, NS5) and HIV-1 gag were performed at baseline, day 7 and 14, and weeks 4, 8, 12, and 24. Among 24 co-infected patients, 21 are males, the mean age was 46±5.8 years, 8 are Caucasian, 12 are African-American and 4 are Hispanic. 20/24 patients were infected with genotype 1, 3/24 patients with genotype 2, and 1/24 with genotype 3a. Results: Pharmacokinetics: To date, 21 patients have been evaluated. 10/21 patients were end of treatment responders, but 2 of these were "late responders" (i.e. HCV RNA declines after week 8 and is undetectable by week 24). Data fitting during the first seven days revealed a free virion clearance rate  $c$  of 13.3 (day<sup>-1</sup>) and an infected cell clearance rate  $\delta$  of 0.21 (day<sup>-1</sup>). The half-lives were 2.7 hours and 4.0 days, respectively. Pharmacodynamics: Viron production was blocked after the first dose of PEG-IFN alfa with an average maximum effectiveness (epsilon<sub>max</sub>) of 89%. We estimated that the fifty percent effective concentration (EC<sub>50</sub>) of PEG-IFN alfa2b, the theoretical in vivo drug concentration at which the drug efficacy is 50%, was five-fold lower in responders compared with non-responders while the maximum (C<sub>max</sub>) and minimum (C<sub>min</sub>) concentrations did not differ significantly. The calculated minimum (epsilon<sub>min</sub>) and maximum (epsilon<sub>max</sub>) efficacy were also significantly increased in responders. Immunologic: The mean number of CD4+, CD8+ and CD56+ cells did not differ significantly at baseline or during treatment between responders and nonresponders. Peripheral blood CD4+ HCV-specific proliferative responses did not differ significantly between responders and nonresponders except that the response to core antigen was increased in non-responders compared with responders at weeks 4 and 12. HIV gag CD4+ proliferative responses were stronger than HCV-specific responses at all time points evaluated. Conclusions: The serum PEG-IFN alfa2b concentration necessary for an end of treatment response is five-fold lower in responders compared with non-responders while there are no significant differences in the maximum and minimum PEG-IFN alfa2b concentrations in responders and nonresponders. These data suggest that host factors responsible for a viral response may be different in responders compared with nonresponders, independent of serum PEG-IFN alfa2b concentrations.

L19 ANSWER 8 OF 12 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2004:14174 BIOSIS

DOCUMENT NUMBER: PREV200400015834

TITLE: Antiviral effect of Ribavirin in early non-responders to interferon monotherapy assessed by kinetics of Hepatitis C virus RNA and HCV Core antigen.

AUTHOR(S): Veillon, P. [Reprint Author]; Payan, C. [Reprint Author]; Fouchard-Hubert, I.; Loustaud-Ratti, V.; Lunel-Fabiani, F. [Reprint Author]; Fontevraud Study Group

CORPORATE SOURCE: Laboratoire de Bacterio-Virologie, CHU Angers, Angers, France

SOURCE: Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, (2003) Vol. 43, pp. 503. print. Meeting Info.: 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA. September 14-17, 2003. American Society for Microbiology.

DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)

LANGUAGE:- English

ENTRY DATE: Entered STN: 24 Dec 2003

Last Updated on STN: 24 Dec 2003

AB Background: We conducted a trial including 203 patients with chronic hepatitis C, naives of treatment, evaluating the antiviral efficiency of Ribavirin, given in second intention in non-responders to interferon alone, by studying viral kinetics. Methods: Patients were treated with interferon at the dosage of 3 or 6 million units three times a week with or without Ribavirin according to response under treatment. Viral kinetics were assessed during treatment follow-up by serial measurements of HCV RNA (bDNA 3.0 and Monitor 2.0) and a new serological assay developed by Ortho-Clinical Diagnostics able to quantify total Hepatitis C virus (HCV) core antigen (HCV cAg). Results: A significant initial drop in HCV RNA or HCV cAg, under interferon alone, was associated with response to therapy ( $-4.85 \pm 1.33$  log for HCV RNA in sustained responders to interferon monotherapy versus  $-1.86 \pm 1.53$  log for others groups,  $p < 0.001$ ). In-patients receiving Ribavirin in second intention, we also observed a similar drop in HCV RNA and HCV cAg, predictive of sustained response ( $-2.67 \pm 1.26$  log for HCV RNA in sustained responders versus  $-0.44 \pm 0.49$  log in non-responders,  $p < 0.001$ ). The positive predictive value (PPV) and the negative predictive value (NPV) were, respectively, 100% and 43% of an undetectable HCV RNA, 93% and 67% of an undetectable HCV core antigen, after one month of treatment. At 3 months of treatment, the PPV and NPV were, respectively, 100% and 66% for HCV RNA, 95% and 90% for HCV cAg. Conclusions: These results support that Ribavirin has a clear antiviral effect in interferon treated patients and that kinetics of HCV RNA and HCV



Core antigen under interferon plus Ribavirin treatment  
are highly predictive of a sustained virological response.

L19 ANSWER 9 OF 12 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN

ACCESSION NUMBER: 2002:618359 BIOSIS

DOCUMENT NUMBER: PREV200200618359

TITLE: Hepatitis C core antigen  
response to treatment with pegylated interferon  
and ribavirin.

AUTHOR(S): Zacks, Steven [Reprint author]; Peace-Brewer, Amy [Reprint  
author]; Orton, Susan [Reprint author]; Theodore, Dickens  
[Reprint author]; Pusek, Susan [Reprint author]; Shrestha,  
Roshan [Reprint author]; Fried, Michael W. [Reprint author]

CORPORATE SOURCE: University of North Carolina at Chapel Hill, Chapel Hill,  
NC, USA

SOURCE: Hepatology, (October, 2002) Vol. 36, No. 4 Part 2, pp.  
356A. print.

Meeting Info.: 53rd Annual Meeting on the Liver. BOSTON,  
MA, USA. November 01-05, 2002.

CODEN: HPTLD9. ISSN: 0270-9139.

DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 4 Dec 2002  
Last Updated on STN: 4 Dec 2002

L19 ANSWER 10 OF 12 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2002:463894 BIOSIS

DOCUMENT NUMBER: PREV200200463894

TITLE: CD4 T lymphocyte proliferative responses to hepatitis C  
virus (HCV) antigens in patients coinfectd with HCV and  
human immunodeficiency virus who responded to anti-HCV  
treatment.

AUTHOR(S): Legrand, Elisabeth; Neau, Didier [Reprint author];  
Galperine, Tatiana; Trimoulet, Pascale; Moreau,  
Jean-Francois; Pitard, Vincent; Lacut, Jean-Yves; Ragnaud,  
Jean-Marie; Dupon, Michel; Le Bail, Brigitte; Bernard,  
Noelle; Schvoerer, Evelyne; Houghton, Michael; Fleury,  
Herve; Lafon, Marie-Edith

CORPORATE SOURCE: Federation de Maladies Infectieuses, Hopital Pellegrin,  
Place Amelie Raba Leon, 33076, Bordeaux cedex, France  
didier.neau@chu-bordeaux.fr

SOURCE: Journal of Infectious Diseases, (1 August, 2002) Vol. 186,

No. 3, pp. 302-311. print.

CODEN: JIDIAQ. ISSN: 0022-1899.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 28 Aug 2002

Last Updated on STN: 28 Aug 2002

AB CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens were evaluated before and during an anti-HCV regimen (interferon-alpha2a and ribavirin) in 36 patients coinfectd with HCV and human immunodeficiency virus (HIV), to determine whether immune responses against HCV antigens are present in such patients, whether these responses are modified by anti-HCV treatment, and whether they are correlated with treatment efficacy. The CD4 responses against HCV antigens (primarily core antigens ) detected at study entry in one-half of the patients did not correlate with anti-HCV treatment efficacy. Of 36 patients, 8 had patterns of persistent immune response to infection by genotypes 3 or 4 that were significantly correlated with sustained virologic response. Persistent immunologic reactivity and sustained virologic response coexisted only in patients infected with genotype 3. These findings suggest that HCV genotype may influence specific immune response, which, in turn, is implicated in virologic control.

L19 ANSWER 11 OF 12 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2002:76839 BIOSIS

DOCUMENT NUMBER: PREV200200076839

TITLE: Ribavirin enhances interferon-gamma levels in patients with chronic hepatitis C treated with interferon-alpha.

AUTHOR(S): Fang, Shih-Hua; Lai, Ming-Yang; Hwang, Lih-Hwa; Yang, Pei-Ming; Chen, Pei-Jer; Chiang, Bor-Luen [Reprint author]; Chen, Ding-Shinn

CORPORATE SOURCE: Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, No. 1, Chang-Teh Street, Taipei, 100, Taiwan  
gicmbor@ha.mc.ntu.edu.tw

SOURCE: Journal of Biomedical Science, (November-December, 2001) .  
Vol. 8, No. 6, pp. 484-491. print.  
ISSN: 1021-7770.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 16 Jan 2002

Last Updated on STN: 25 Feb 2002

AB Some patients with chronic hepatitis C respond to interferon (IFN)-alpha treatment, and the efficiency can be improved by

combining it with ribavirin. The mechanism of this improvement is unknown. To investigate the effects of these two regimens on the immune responses in 51 patients with chronic hepatitis C, we examined the hepatitis C core antigen-specific proliferative response and cytokine production profiles, natural killer (NK) cell cytotoxicity and cytotoxic T cell function during treatment. The results are as follows: (1) both viral clearance and biochemical normalization occurred more frequently in patients receiving combination therapy; (2) the function of NK cells increased after treatment in the responders of both groups ( $p < 0.05$ ); (3) the level of IFN-gamma produced by hepatitis C core antigen-stimulated peripheral blood mononuclear cells was higher in patients receiving combination therapy, especially in responders; (4) the core antigen-specific proliferative response decreased after treatment, and (5) in addition, the core-specific cytotoxic T cell activities of five responder patients also increased significantly after therapy. In conclusion, enhancement of immune responses, especially those related to type-1 T helper cell activity, may contribute to better efficacy in combining ribavirin with IFN-alpha for treatment of chronic hepatitis C.

L19 ANSWER 12 OF 12 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2001:528598 BIOSIS

DOCUMENT NUMBER: PREV200100528598

TITLE: Hepatitis C virus (HCV) core  
antigen kinetics during treatment of  
chronic hepatitis C with interferon alpha and/or  
ribavirin.

AUTHOR(S): Dahari, Harel [Reprint author]; Hezode, Christophe;  
Bouvier-Alias, Magali; Dhumeaux, Daniel; Neumann, Avidan  
U.; Pawlotsky, Jean-Michel

CORPORATE SOURCE: Bar-Ilan Univ, Bar-Ilan, Israel

SOURCE: Hepatology, (October, 2001) Vol. 34, No. 4 Pt. 2, pp. 217A.  
print.

Meeting Info.: 52nd Annual Meeting and Postgraduate Courses  
of the American Association for the Study of Liver  
Diseases. Dallas, Texas, USA. November 09-13, 2001.

CODEN: HPTLD9. ISSN: 0270-9139.

DOCUMENT TYPE: Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 14 Nov 2001

Last Updated on STN: 23 Feb 2002

=> D L20 IBIB TI 1-18

L20 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:549206 CAPLUS

DOCUMENT NUMBER: 145:58344

TITLE: How to use viral genomic analysis in clinical practice  
chronic hepatitis B and C

AUTHOR(S): Izumi, Namiki

CORPORATE SOURCE: Dep. Gastroenterol. Hepatol., Musashino Red Cross  
Hospital, Musashino, 180-8610, Japan

SOURCE: Rinsho Byori (2006), 54(4), 395-399

CODEN: RBYOAI; ISSN: 0047-1860

PUBLISHER: Nippon Rinsho Kensa Igakkai

DOCUMENT TYPE: Journal; General Review

LANGUAGE: Japanese

TI How to use viral genomic analysis in clinical practice chronic  
hepatitis B and C

L20 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:137679 CAPLUS

DOCUMENT NUMBER: 145:61030

TITLE: Fundamental evaluation and clinical efficacy of high  
sensitive HCV-core antigen  
measurement assay

AUTHOR(S): Fukuda, Mika; Yatsushashi, Hiroshi; Yano, Koji; Oguro,  
Manabu; Ishibashi, Ohmi; Takezaki, Eiichi; Hirooka,  
Taizo; Sakai, Hironori; Muro, Toyokichi; Masaki,  
Naohiko; Komatsu, Tatsuji; Morimoto, Hideo; Saoshiro,  
Jobu; Masumoto, Akihito; Sodeyama, Takeshi; Shimada,  
Masaaki; Santo, Takehiro; Watanabe, Yukio; Chida,  
Nobuyuki; Ohara, Yukio; Yamashita, Haruhiro; Harada,  
Eiji

CORPORATE SOURCE: Clinical Research Center, Nagasaki Medical Center,  
Japan

SOURCE: Igaku to Yakugaku (2005), 54(5), 677-682

CODEN: IGYAEI; ISSN: 0389-3898

PUBLISHER: Shizen Kagakusha

DOCUMENT TYPE: Journal

LANGUAGE: Japanese

TI Fundamental evaluation and clinical efficacy of high sensitive HCV-  
core antigen measurement assay

L20 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1071799 CAPLUS

DOCUMENT NUMBER: 144:218886

TITLE: Leucocytapheresis with Adacolumn enhances HCV-specific

proliferative responses in patients infected with  
hepatitis C virus genotypes 1  
AUTHOR(S): Diepolder, Helmut M.; Kashiwagi, Nobuhito; Teuber,  
Gerlinde; Ulsenheimer, Axel; Franz, Marita; Yokoyama,  
Takashi; Zachoval, Reinhart  
CORPORATE SOURCE: Institute for Immunology, University of Munich,  
Germany  
SOURCE: Journal of Medical Virology (2005), 77(2), 209-215  
CODEN: JMVIDB; ISSN: 0146-6615  
PUBLISHER: Wiley-Liss, Inc.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI Leucocytophoresis with Adacolumn enhances HCV-specific proliferative  
responses in patients infected with hepatitis C virus genotypes  
1  
REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES  
AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:526344 CAPLUS

DOCUMENT NUMBER: 141:241642

TITLE: The predictive value of core antigen  
testing for the management of hepatitis C  
patients receiving pegylated interferon/  
ribavirin treatment

AUTHOR(S): Pradat, Pierre; Maynard, Marianne; Buti, Maria;  
Berthillon, Pascale; Picchio, Gaston; Tillmann, Hans  
L.; Wiegand, Johannes; Voirin, Nicolas; Manns, Michael  
P.; Esteban, Juan-Ignacio; Martinot, Michele;  
Marcellin, Patrick; Trepo, Christian

CORPORATE SOURCE: Department of Hepatology, Hotel-Dieu, Lyon, Fr.

SOURCE: Journal of Medical Virology (2004), 73(3), 392-396

CODEN: JMVIDB; ISSN: 0146-6615

PUBLISHER: Wiley-Liss, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

TI The predictive value of core antigen testing for the  
management of hepatitis C patients receiving pegylated  
interferon/ribavirin treatment

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:269702 CAPLUS

DOCUMENT NUMBER: 139:83680  
TITLE: Concomitant augmentation of type 1 CD4+ and CD8+  
T-cell responses during successful interferon-.alpha.  
and ribavirin treatment for  
chronic hepatitis C virus infection  
AUTHOR(S): Sreenarasimhaiah, Jayaprakash; Jaramillo, Andres;  
Crippin, Jeffrey; Lisker-Melman, Mauricio; Chapman,  
William C.; Mohanakumar, T.  
CORPORATE SOURCE: Department of Gastroenterology, Washington University  
School of Medicine, St. Louis, MO, USA  
SOURCE: Human Immunology (2003), 64(5), 497-504  
CODEN: HUIMDQ; ISSN: 0198-8859  
PUBLISHER: Elsevier Science Inc.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during  
successful interferon-.alpha. and ribavirin treatment  
for chronic hepatitis C virus infection  
REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES  
AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:682658 CAPLUS

DOCUMENT NUMBER: 138:23465

TITLE: CD4 T lymphocyte proliferative responses to  
hepatitis C virus (HCV) antigens in patients  
coinfectd with HCV and human immunodeficiency virus  
who responded to anti-HCV treatment

AUTHOR(S): Legrand, Elisabeth; Neau, Didier; Galperine, Tatiana;  
Trimoulet, Pascale; Moreau, Jean-Francois; Pitard,  
Vincent; Lacut, Jean-Yves; Ragnaud, Jean-Marie; Dupon,  
Michel; Le Bail, Brigitte; Bernard, Noelle; Schvoerer,  
Evelyne; Houghton, Michael; Fleury, Herve; Lafon,  
Marie-Edith

CORPORATE SOURCE: Virology Laboratory, Bordeaux 2 University, Fr.

SOURCE: Journal of Infectious Diseases (2002), 186(3), 302-311

CODEN: JIDIAQ; ISSN: 0022-1899

PUBLISHER: University of Chicago Press

DOCUMENT TYPE: Journal

LANGUAGE: English

TI CD4 T lymphocyte proliferative responses to hepatitis C virus  
(HCV) antigens in patients coinfectd with HCV and human immunodeficiency  
virus who responded to anti-HCV treatment

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES

AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:871451 CAPLUS

DOCUMENT NUMBER: 136:368372

TITLE: Functional measurement of hepatitis C virus  
core-specific CD8+ T-cell responses in the livers or  
peripheral blood of patients by using autologous  
peripheral blood mononuclear cells as targets or  
stimulators

AUTHOR(S): Fang, Shih-Hua; Chiang, Bor-Luen; Wu, Mei-Hua; Iba,  
Hideo; Lai, Ming-Yang; Yang, Pei-Ming; Chen,  
Ding-Shinn; Hwang, Lih-Hwa

CORPORATE SOURCE: Graduate Institute of Microbiology, College of  
Medicine, National Taiwan University, National Taiwan  
University Hospital, Taipei, 100, Taiwan

SOURCE: Journal of Clinical Microbiology (2001), 39(11),  
3895-3901

CODEN: JCMIDW; ISSN: 0095-1137

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Functional measurement of hepatitis C virus core-specific CD8+  
T-cell responses in the livers or peripheral blood of patients by using  
autologous peripheral blood mononuclear cells as targets or stimulators

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:813914 CAPLUS

DOCUMENT NUMBER: 137:27954

TITLE: Ribavirin Enhances Interferon- gamma. Levels  
in Patients with Chronic Hepatitis C Treated  
with Interferon- alpha.

AUTHOR(S): Fang, Shih-Hua; Lai, Ming-Yang; Hwang, Lih-Hwa; Yang,  
Pei-Ming; Chen, Pei-Jer; Chiang, Bor-Luen; Chen,  
Ding-Shinn

CORPORATE SOURCE: Graduate Institute of Microbiology, National Taiwan  
University, Taipei, Taiwan

SOURCE: Journal of Biomedical Science (Basel, Switzerland)  
(2001), 8(6), 484-491

CODEN: JBCIEA; ISSN: 1021-7770

PUBLISHER: S. Karger AG

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Ribavirin Enhances Interferon- $\gamma$ . Levels in Patients with  
Chronic Hepatitis C Treated with Interferon- $\alpha$ .

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:13875 CAPLUS

DOCUMENT NUMBER: 128:85155

TITLE: Synthetic genes for hepatitis C virus  
antigens for vaccine use

INVENTOR(S): Donnelly, John J.; Lu, Tong-Ming; Liu, Margaret A.;  
Shiver, John W.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9747358	A1	19971218	WO 1997-US9884	19970606
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2257137	AA	19971218	CA 1997-2257137	19970606
AU 9733808	A1	19980107	AU 1997-33808	19970606
AU 717542	B2	20000330		
EP 1009763	A1	20000621	EP 1997-929842	19970606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002500502	T2	20020108	JP 1998-501722	19970606
US 2003053987	A1	20030320	US 2000-194949	20000217
US 6653125	B2	20031125		
US 2005074752	A1	20050407	US 2003-664391	20030917
PRIORITY APPLN. INFO.: US 1996-20494P P 19960611				
GB 1996-14731 A 19960712				
US 1996-33534P P 19961220				
WO 1997-US9884 W 19970606				
US 2000-194949 A1 20000217				

TI Synthetic genes for hepatitis C virus antigens for vaccine use



L20 ANSWER 10 OF 18 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2004:325700 BIOSIS

DOCUMENT NUMBER: PREV200400327000

TITLE: The predictive value of core antigen  
testing for the management of hepatitis C  
patients receiving pegylated interferon/ribavirin  
treatment.

AUTHOR(S): Pradat, Pierre [Reprint Author]; Maynard, Marianne; Buti,  
Maria; Berthillon, Pascale; Picchio, Gaston; Tillmann, Hans  
L.; Wiegand, Johannes; Voirin, Nicolas; Manns, Michael P.;  
Esteban, Juan-Ignacio; Martinot, Michele; Marcellin,  
Patrick; Trepo, Christian

CORPORATE SOURCE: Dept Hepatol, Hop Hotel Dieu, 1,Pl Hop, F-69288, Lyon, 02,  
France  
pradat@univ-lyon1.fr

SOURCE: Journal of Medical Virology, (July 2004) Vol. 73, No. 3,  
pp. 392-396. print.

CODEN: JMVIDB. ISSN: 0146-6615.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 29 Jul 2004

Last Updated on STN: 29 Jul 2004

TI The predictive value of core antigen testing for the  
management of hepatitis C patients receiving pegylated  
interferon/ribavirin treatment.

L20 ANSWER 11 OF 18 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2004:123681 BIOSIS

DOCUMENT NUMBER: PREV200400116810

TITLE: Pharmacodynamics and pharmacokinetics of hepatitis  
C virus (HCV) and pegylated interferon-alfa2b in human  
immunodeficiency virus (HIV)/HCV co-infected patients.

AUTHOR(S): Golia, Preeti [Reprint Author]; Powers, Kimberly; Dorante,  
Gary [Reprint Author]; Cunningham-Rundles, Susanna [Reprint  
Author]; Ribeiro, Ruy; Shata, Mohammed T.; Perelson, Alan  
S.; Talal, Andrew H. [Reprint Author]

CORPORATE SOURCE: Weill Medical College of Cornell University, New York, NY,  
USA

SOURCE: Hepatology, (October 2003) Vol. 38, No. 4 Suppl. 1, pp.  
345A. print.

Meeting Info.: 54th Annual Meeting of the American

Association for the Study of Liver Diseases. Boston, MA,  
USA. October 24-28, 2003. American Association for the  
Study of Liver Diseases.  
ISSN: 0270-9139 (ISSN print).

DOCUMENT TYPE: Conference; (Meeting)  
Conference; (Meeting Poster)  
Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 3 Mar 2004

Last Updated on STN: 3 Mar 2004

TI Pharmacodynamics and pharmacokinetics of hepatitis C virus (HCV)  
and pegylated interferon-alfa2b in human immunodeficiency virus (HIV)/HCV  
co-infected patients.

L20 ANSWER 12 OF 18 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2004:14174 BIOSIS

DOCUMENT NUMBER: PREV200400015834

TITLE: Antiviral effect of Ribavirin in early  
non-responders to interferon monotherapy assessed by  
kinetics of Hepatitis C virus RNA and HCV  
Core antigen.

AUTHOR(S): Veillon, P. [Reprint Author]; Payan, C. [Reprint Author];  
Fouchard-Hubert, I.; Loustaud-Ratti, V.; Lunel-Fabiani, F.  
[Reprint Author]; Fontevraud Study Group

CORPORATE SOURCE: Laboratoire de Bacterio-Virologie, CHU Angers, Angers,  
France

SOURCE: Abstracts of the Interscience Conference on Antimicrobial  
Agents and Chemotherapy, (2003) Vol. 43, pp. 503. print.  
Meeting Info.: 43rd Annual Interscience Conference on  
Antimicrobial Agents and Chemotherapy. Chicago, IL, USA.  
September 14-17, 2003. American Society for Microbiology.

DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 24 Dec 2003

Last Updated on STN: 24 Dec 2003

TI Antiviral effect of Ribavirin in early non-responders to  
interferon monotherapy assessed by kinetics of Hepatitis C virus  
RNA and HCV Core antigen.

L20 ANSWER 13 OF 18 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2003:247888 BIOSIS

DOCUMENT NUMBER: PREV200300247888

TITLE: Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during successful interferon-alpha and ribavirin treatment for chronic hepatitis C virus infection.

AUTHOR(S): Sreenarasimhaiah, Jayaprakash; Jaramillo, Andres; Crippin, Jeffrey; Lisker-Melman, Mauricio; Chapman, William C.; Mohanakumar, T. [Reprint Author]

CORPORATE SOURCE: Department of Surgery, Washington University School of Medicine, 660 South Euclid Avenue, CSRB.3328, Box 8109, Saint Louis, MO, 63110, USA  
kumart@msnotes.wustl.edu

SOURCE: Human Immunology, (May 2003) Vol. 64, No. 5, pp. 497-504.  
print.

CODEN: HUIMDQ. ISSN: 0198-8859.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 21 May 2003

Last Updated on STN: 21 May 2003

TI Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during successful interferon-alpha and ribavirin treatment for chronic hepatitis C virus infection.

L20 ANSWER 14 OF 18 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2002:618359 BIOSIS

DOCUMENT NUMBER: PREV200200618359

TITLE: Hepatitis C core antigen  
response to treatment with pegylated interferon  
and ribavirin.

AUTHOR(S): Zacks, Steven [Reprint author]; Peace-Brewer, Amy [Reprint author]; Orton, Susan [Reprint author]; Theodore, Dickens [Reprint author]; Pusek, Susan [Reprint author]; Shrestha, Roshan [Reprint author]; Fried, Michael W. [Reprint author]

CORPORATE SOURCE: University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

SOURCE: Hepatology, (October, 2002) Vol. 36, No. 4 Part 2, pp. 356A. print.

Meeting Info.: 53rd Annual Meeting on the Liver. BOSTON, MA, USA. November 01-05, 2002.

CODEN: HPTLD9. ISSN: 0270-9139.

DOCUMENT TYPE: Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 4 Dec 2002

Last Updated on STN: 4 Dec 2002

TI Hepatitis C core antigen response to  
treatment with pegylated interferon and ribavirin.

L20 ANSWER 15 OF 18 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2002:463894 BIOSIS

DOCUMENT NUMBER: PREV200200463894

TITLE: CD4 T lymphocyte proliferative responses to  
hepatitis C virus (HCV) antigens in patients  
coinfected with HCV and human immunodeficiency virus who  
responded to anti-HCV treatment.

AUTHOR(S): Legrand, Elisabeth; Neau, Didier [Reprint author];  
Galperine, Tatiana; Trimoulet, Pascale; Moreau,  
Jean-Francois; Pitard, Vincent; Lacut, Jean-Yves; Ragnaud,  
Jean-Marie; Dupon, Michel; Le Bail, Brigitte; Bernard,  
Noelle; Schvoerer, Evelyne; Houghton, Michael; Fleury,  
Herve; Lafon, Marie-Edith

CORPORATE SOURCE: Federation de Maladies Infectieuses, Hopital Pellegrin,  
Place Amelie Raba Leon, 33076, Bordeaux cedex, France  
didier.neau@chu-bordeaux.fr

SOURCE: Journal of Infectious Diseases, (1 August, 2002) Vol. 186,  
No. 3, pp. 302-311. print.

CODEN: JIDIAQ. ISSN: 0022-1899.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 28 Aug 2002

Last Updated on STN: 28 Aug 2002

TI CD4 T lymphocyte proliferative responses to hepatitis C virus  
(HCV) antigens in patients coinfectd with HCV and human immunodeficiency  
virus who responded to anti-HCV treatment.

L20 ANSWER 16 OF 18 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2002:76839 BIOSIS

DOCUMENT NUMBER: PREV200200076839

TITLE: Ribavirin enhances interferon-gamma levels in  
patients with chronic hepatitis C treated with  
interferon-alpha.

AUTHOR(S): Fang, Shih-Hua; Lai, Ming-Yang; Hwang, Lih-Hwa; Yang,  
Pei-Ming; Chen, Pei-Jer; Chiang, Bor-Luen [Reprint author];  
Chen, Ding-Shinn

CORPORATE SOURCE: Graduate Institute of Clinical Medicine, College of  
Medicine, National Taiwan University, No. 1, Chang-Teh

Street, Taipei, 100, Taiwan  
gicmbor@ha.mc.ntu.edu.tw

SOURCE: Journal of Biomedical Science, (November-December, 2001)  
Vol. 8, No. 6, pp. 484-491. print.  
ISSN: 1021-7770.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 16 Jan 2002

Last Updated on STN: 25 Feb 2002

TI Ribavirin enhances interferon-gamma levels in patients with  
chronic hepatitis C treated with interferon-alpha.

L20 ANSWER 17 OF 18 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2001:528598 BIOSIS

DOCUMENT NUMBER: PREV200100528598

TITLE: Hepatitis C virus (HCV) core  
antigen kinetics during treatment of  
chronic hepatitis C with interferon alpha and/or  
ribavirin.

AUTHOR(S): Dahari, Harel [Reprint author]; Hezode, Christophe;  
Bouvier-Alias, Magali; Dhumeaux, Daniel; Neumann, Avidan  
U.; Pawlotsky, Jean-Michel

CORPORATE SOURCE: Bar-Ilan Univ, Bar-Ilan, Israel

SOURCE: Hepatology, (October, 2001) Vol. 34, No. 4 Pt. 2, pp. 217A.  
print.

Meeting Info.: 52nd Annual Meeting and Postgraduate Courses  
of the American Association for the Study of Liver  
Diseases. Dallas, Texas, USA. November 09-13, 2001.

CODEN: HPTLD9. ISSN: 0270-9139.

DOCUMENT TYPE: Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 14 Nov 2001

Last Updated on STN: 23 Feb 2002

TI Hepatitis C virus (HCV) core antigen  
kinetics during treatment of chronic hepatitis C with  
interferon alpha and/or ribavirin.

L20 ANSWER 18 OF 18 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2001:52853 BIOSIS

DOCUMENT NUMBER: PREV200100052853

TITLE: Hepatitis B virus-specific T-cell proliferation

and cytokine secretion in chronic hepatitis B e  
antibody-positive patients treated with ribavirin  
and interferon alfa.

AUTHOR(S): Rico, Miguel A.; Quiroga, Juan Antonio; Subira, Dolores;  
Castanon, Susana; Esteban, Jose Miguel; Pardo, Margarita;  
Carreno, Vicente [Reprint author]

CORPORATE SOURCE: Fundacion para el Estudio de las Hepatitis Virales, C/  
Guzman el Bueno, 72, 28015, Madrid, Spain  
fehvv@tdi.es

SOURCE: Hepatology, (January, 2001) Vol. 33, No. 1, pp. 295-300.  
print.

CODEN: HPTLD9. ISSN: 0270-9139.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 24 Jan 2001

Last Updated on STN: 12 Feb 2002

TI Hepatitis B virus-specific T-cell proliferation and cytokine  
secretion in chronic hepatitis B e antibody-positive patients  
treated with ribavirin and interferon alfa.

=> D L8 IBIB TI 1-50

L8 ANSWER 1 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:549206 CAPLUS

DOCUMENT NUMBER: 145:58344

TITLE: How to use viral genomic analysis in clinical practice  
chronic hepatitis B and C

AUTHOR(S): Izumi, Namiki

CORPORATE SOURCE: Dep. Gastroenterol. Hepatol., Musashino Red Cross  
Hospital, Musashino, 180-8610, Japan

SOURCE: Rinsho Byori (2006), 54(4), 395-399

CODEN: RBYOAI; ISSN: 0047-1860

PUBLISHER: Nippon Rinsho Kensa Igakkai

DOCUMENT TYPE: Journal; General Review

LANGUAGE: Japanese

TI How to use viral genomic analysis in clinical practice chronic  
hepatitis B and C

L8 ANSWER 2 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:210281 CAPLUS

TITLE: Comparison of serum hepatitis C virus (HCV)  
RNA and core antigen levels in  
patients coinfectd with human immunodeficiency virus  
and HCV and treated with inteferon plus  
ribavirin

AUTHOR(S): Pivert, A.; Payan, C.; Morand, P.; Fafi-Kremer, S.;  
Deshayes, J.; Carrat, F.; Pol, S.; Cacoub, P.;  
Perronne, C.; Lunel, F.  
CORPORATE SOURCE: Laboratoire de Bacteriologie-Virologie-Hygiene  
Hospitaliere, CHU Angers, Fr.  
SOURCE: Journal of Clinical Microbiology (2006), 44(2),  
417-422  
CODEN: JCMIDW; ISSN: 0095-1137  
PUBLISHER: American Society for Microbiology  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI Comparison of serum hepatitis C virus (HCV) RNA and core  
antigen levels in patients coinfectd with human immunodeficiency  
virus and HCV and treated with inteferfon plus ribavirin  
REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES  
AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:137679 CAPLUS

DOCUMENT NUMBER: 145:61030

TITLE: Fundamental evaluation and clinical efficacy of high  
sensitive HCV-core antigen  
measurement assay

AUTHOR(S): Fukuda, Mika; Yatsushashi, Hiroshi; Yano, Koji; Oguro,  
Manabu; Ishibashi, Ohmi; Takezaki, Eiichi; Hirooka,  
Taizo; Sakai, Hironori; Muro, Toyokichi; Masaki,  
Naohiko; Komatsu, Tatsuji; Morimoto, Hideo; Saoshiro,  
Jobu; Masumoto, Akihhide; Sodeyama, Takeshi; Shimada,  
Masaaki; Santo, Takehiro; Watanabe, Yukio; Chida,  
Nobuyuki; Ohara, Yukio; Yamashita, Haruhiro; Harada,  
Eiji

CORPORATE SOURCE: Clinical Research Center, Nagasaki Medical Center,  
Japan

SOURCE: Igaku to Yakugaku (2005), 54(5), 677-682

CODEN: IGYAEI; ISSN: 0389-3898

PUBLISHER: Shizen Kagakusha

DOCUMENT TYPE: Journal

LANGUAGE: Japanese

TI Fundamental evaluation and clinical efficacy of high sensitive HCV-  
core antigen measurement assay

L8 ANSWER 4 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1071799 CAPLUS

DOCUMENT NUMBER: 144:218886

TITLE: Leucocyapheresis with Adacolumn enhances HCV-specific

proliferative responses in patients infected with  
hepatitis C virus genotypes 1

AUTHOR(S): Diepolder, Helmut M.; Kashiwagi, Nobuhito; Teuber,  
Gerlinde; Ulsenheimer, Axel; Franz, Marita; Yokoyama,  
Takashi; Zachoval, Reinhart

CORPORATE SOURCE: Institute for Immunology, University of Munich,  
Germany

SOURCE: Journal of Medical Virology (2005), 77(2), 209-215  
CODEN: JMVIDB; ISSN: 0146-6615

PUBLISHER: Wiley-Liss, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Leucocytopheresis with Adacolumn enhances HCV-specific proliferative  
responses in patients infected with hepatitis C virus genotypes  
1

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES  
AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:49428 CAPLUS

DOCUMENT NUMBER: 142:334473

TITLE: The role of core antigen detection  
in management of hepatitis C: a critical  
review

AUTHOR(S): Seme, Katja; Poljak, Mario; Babic, Dunja Z.; Mocilnik,  
Tina; Vince, Adriana

CORPORATE SOURCE: Institute of Microbiology and Immunology, Medical  
Faculty, Ljubljana, 1000, Slovenia

SOURCE: Journal of Clinical Virology (2005), 32(2), 92-101  
CODEN: JCVIFB; ISSN: 1386-6532

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

TI The role of core antigen detection in management of  
hepatitis C: a critical review

REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES  
AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:939911 CAPLUS

DOCUMENT NUMBER: 142:153868

TITLE: Comparison of the RNA and antigen kinetics of the  
hepatitis C virus capsid following  
therapeutics in patients co-infected by the



hepatitis C virus and the human  
immunodeficiency virus, treated by dual interferon-  
ribavirin therapy according to the RIBAVIC  
protocol

AUTHOR(S): Pivert, A.; Payan, C.; Lunel, F.  
CORPORATE SOURCE: Laboratoire de bacteriologie virologie hygiene  
hospitaliere, CHU de Angers, Fr.  
SOURCE: Pathologie Biologie (2004), 52(9), 522-528  
CODEN: PTBIAN; ISSN: 0369-8114  
PUBLISHER: Editions Scientifiques et Medicales Elsevier  
DOCUMENT TYPE: Journal  
LANGUAGE: French  
TI Comparison of the RNA and antigen kinetics of the hepatitis C  
virus capsid following therapeutics in patients co-infected by the  
hepatitis C virus and the human immunodeficiency virus, treated by  
dual interferon-ribavirin therapy according to the RIBAVIC  
protocol  
REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:863378 CAPLUS

DOCUMENT NUMBER: 142:21288

TITLE: Serum levels of hepatitis C virus  
core antigen as a marker of  
infection and response to therapy

AUTHOR(S): Soffredini, Roberta; Rumi, Maria Grazia; Parravicini,  
Maria Luisa; Ronchi, Guido; Del Ninno, Ersilio; Russo,  
Antonio; Colombo, Massimo

CORPORATE SOURCE: A.M. Migliavacca Center for Liver Disease, Department  
of Gastroenterology and Endocrinology, IRCSS Maggiore  
Hospital and University of Milan, Milan, Italy

SOURCE: American Journal of Gastroenterology (2004), 99(9),  
1738-1743

CODEN: AJGAAR; ISSN: 0002-9270

PUBLISHER: Blackwell Publishing, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Serum levels of hepatitis C virus core antigen  
as a marker of infection and response to therapy

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:526344 CAPLUS  
DOCUMENT NUMBER: 141:241642  
TITLE: The predictive value of core antigen  
testing for the management of hepatitis C  
patients receiving pegylated interferon/  
ribavirin treatment  
AUTHOR(S): Pradat, Pierre; Maynard, Marianne; Buti, Maria;  
Berthillon, Pascale; Picchio, Gaston; Tillmann, Hans  
L.; Wiegand, Johannes; Voirin, Nicolas; Manns, Michael  
P.; Esteban, Juan-Ignacio; Martinot, Michele;  
Marcellin, Patrick; Trepo, Christian  
CORPORATE SOURCE: Department of Hepatology, Hotel-Dieu, Lyon, Fr.  
SOURCE: Journal of Medical Virology (2004), 73(3), 392-396  
CODEN: JMVIDB; ISSN: 0146-6615  
PUBLISHER: Wiley-Liss, Inc.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI The predictive value of core antigen testing for the  
management of hepatitis C patients receiving pegylated  
interferon/ribavirin treatment  
REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES  
AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:151128 CAPLUS  
DOCUMENT NUMBER: 141:52620  
TITLE: Hepatitis C virus Core  
Antigen as a predictor of non-response in  
genotype 1 chronic hepatitis C patients  
treated with peginterferon .alpha.-2b plus  
ribavirin  
AUTHOR(S): Buti, Maria; Mendez, Claudia; Schaper, Melanie;  
Sauleda, Silvia; Valdes, Auristela; Rodriguez-Frias,  
Francisco; Jardi, Rosendo; Esteban, Rafael  
CORPORATE SOURCE: Servicio de Hepatologia, Hospital General  
Universitario Valle de Hebron, Barcelona, Spain  
SOURCE: Journal of Hepatology (2004), 40(3), 527-532  
CODEN: JOHEEC; ISSN: 0168-8278  
PUBLISHER: Elsevier Science B.V.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI Hepatitis C virus Core Antigen as a  
predictor of non-response in genotype 1 chronic hepatitis C  
patients treated with peginterferon .alpha.-2b plus ribavirin

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:803854 CAPLUS

DOCUMENT NUMBER: 140:314463

TITLE: Antiviral effect of ribavirin in early  
non-responders to interferon monotherapy assessed by  
kinetics of hepatitis C virus RNA and  
hepatitis C virus core  
antigen

AUTHOR(S): Lunel, Françoise; Veillon, Pascal; Fouchard-Hubert,  
Isabelle; Loustaud-Ratti, Veronique; Abergel, Armand;  
Silvain, Christine; Rifflet, Herve; Blanchi, Alain;  
Causse, Xavier; Bacq, Yannick; Payan, Christopher

CORPORATE SOURCE: Laboratoire de Bacteriologie-Virologie, CHU Angers,  
Angers, 49033, Fr.

SOURCE: Journal of Hepatology (2003), 39(5), 826-833

CODEN: JOHEEC; ISSN: 0168-8278

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Antiviral effect of ribavirin in early non-responders to  
interferon monotherapy assessed by kinetics of hepatitis C virus  
RNA and hepatitis C virus core antigen

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 11 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:720757 CAPLUS

DOCUMENT NUMBER: 140:122135

TITLE: Monitoring response to antiviral therapy for patients  
with chronic hepatitis C virus infection by  
a core-antigen assay

AUTHOR(S): Rebucci, Chiara; Cerino, Antonella; Cividini,  
Agostino; Timo, Letizia; Furione, Milena; Mondelli,  
Mario U.

CORPORATE SOURCE: Dipartimento di Malattie Infettive, I.R.C.C.S.  
Policlinico San Matteo and Università degli Studi di  
Pavia, Pavia, Italy

SOURCE: Journal of Clinical Microbiology (2003), 41(8),  
3881-3884

CODEN: JCMIDW; ISSN: 0095-1137

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Monitoring response to antiviral therapy for patients with chronic hepatitis C virus infection by a core-antigen assay

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:641541 CAPLUS

DOCUMENT NUMBER: 140:319156

TITLE: Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and Amplicor Monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy

AUTHOR(S): Veillon, Pascal; Payan, Christopher; Picchio, Gaston; Maniez-Montreuil, Michele; Guntz, Philippe; Lunel, Francoise

CORPORATE SOURCE: Laboratoire de Bacterio-Virologie, CHU Angers, Angers, Fr.

SOURCE: Journal of Clinical Microbiology (2003), 41(7), 3212-3220

CODEN: JCMIDW; ISSN: 0095-1137

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and Amplicor Monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 13 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:269702 CAPLUS

DOCUMENT NUMBER: 139:83680

TITLE: Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during successful interferon-.alpha. and ribavirin treatment for chronic hepatitis C virus infection

AUTHOR(S): Sreenarasimhaiah, Jayaprakash; Jaramillo, Andres; Crippin, Jeffrey; Lisker-Melman, Mauricio; Chapman,

William C.; Mohanakumar, T.  
CORPORATE SOURCE: Department of Gastroenterology, Washington University  
School of Medicine, St. Louis, MO, USA  
SOURCE: Human Immunology (2003), 64(5), 497-504  
CODEN: HUIMDQ; ISSN: 0198-8859  
PUBLISHER: Elsevier Science Inc.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during  
successful interferon- $\alpha$  and ribavirin treatment  
for chronic hepatitis C virus infection  
REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 14 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2002:891154 CAPLUS  
DOCUMENT NUMBER: 139:46659  
TITLE: Ribavirin increases mitogen- and  
~~antigen-induced~~ expression of CD40L on CD4+ T cells in  
vivo  
AUTHOR(S): Bergamini, A.; Cepparulo, M.; Bolacchi, F.; Araco, A.;  
Tisone, G.; Ombres, D.; Rocchi, G.; Angelico, M.  
CORPORATE SOURCE: Department of Public Health and Cellular Biology,  
Chair of Infectious Diseases, University of Rome 'Tor  
Vergata', Rome, Italy  
SOURCE: Clinical and Experimental Immunology (2002), 130(2),  
293-299  
CODEN: CEXIAL; ISSN: 0009-9104  
PUBLISHER: Blackwell Science Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI Ribavirin increases mitogen- and antigen-induced expression of  
CD40L on CD4+ T cells in vivo  
REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 15 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2002:682658 CAPLUS  
DOCUMENT NUMBER: 138:23465  
TITLE: CD4 T lymphocyte proliferative responses to  
hepatitis C virus (HCV) antigens in patients  
coinfected with HCV and human immunodeficiency virus  
who responded to anti-HCV treatment  
AUTHOR(S): Legrand, Elisabeth; Neau, Didier; Galperine, Tatiana;

Trimoulet, Pascale; Moreau, Jean-Francois; Pitard,  
Vincent; Lacut, Jean-Yves; Ragnaud, Jean-Marie; Dupon,  
Michel; Le Bail, Brigitte; Bernard, Noelle; Schvoerer,  
Evelyne; Houghton, Michael; Fleury, Herve; Lafon,  
Marie-Edith

CORPORATE SOURCE: Virology Laboratory, Bordeaux 2 University, Fr.

SOURCE: Journal of Infectious Diseases (2002), 186(3), 302-311

CODEN: JIDIAQ; ISSN: 0022-1899

PUBLISHER: University of Chicago Press

DOCUMENT TYPE: Journal

LANGUAGE: English

TI CD4 T lymphocyte proliferative responses to hepatitis C virus  
(HCV) antigens in patients coinfectd with HCV and human immunodeficiency  
virus who responded to anti-HCV treatment

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES

AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 16 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:871451 CAPLUS

DOCUMENT NUMBER: 136:368372

TITLE: Functional measurement of hepatitis C virus  
core-specific CD8+ T-cell responses in the livers or  
peripheral blood of patients by using autologous  
peripheral blood mononuclear cells as targets or  
stimulators

AUTHOR(S): Fang, Shih-Hua; Chiang, Bor-Luen; Wu, Mei-Hua; Iba,  
Hideo; Lai, Ming-Yang; Yang, Pei-Ming; Chen,  
Ding-Shinn; Hwang, Lih-Hwa

CORPORATE SOURCE: Graduate Institute of Microbiology, College of  
Medicine, National Taiwan University, National Taiwan  
University Hospital, Taipei, 100, Taiwan

SOURCE: Journal of Clinical Microbiology (2001), 39(11),  
3895-3901

CODEN: JCMIDW; ISSN: 0095-1137

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Functional measurement of hepatitis C virus core-specific CD8+  
T-cell responses in the livers or peripheral blood of patients by using  
autologous peripheral blood mononuclear cells as targets or stimulators

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES

AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 17 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:813914 CAPLUS  
DOCUMENT NUMBER: 137:27954  
TITLE: Ribavirin Enhances Interferon-.gamma. Levels  
in Patients with Chronic Hepatitis C Treated  
with Interferon-.alpha.  
AUTHOR(S): Fang, Shih-Hua; Lai, Ming-Yang; Hwang, Lih-Hwa; Yang,  
Pei-Ming; Chen, Pei-Jer; Chiang, Bor-Luen; Chen,  
Ding-Shinn  
CORPORATE SOURCE: Graduate Institute of Microbiology, National Taiwan  
University, Taipei, Taiwan  
SOURCE: Journal of Biomedical Science (Basel, Switzerland)  
(2001), 8(6), 484-491  
CODEN: JBCIEA; ISSN: 1021-7770  
PUBLISHER: S. Karger AG  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI Ribavirin Enhances Interferon-.gamma. Levels in Patients with  
Chronic Hepatitis C Treated with Interferon-.alpha.  
REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES  
AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 18 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2000:171938 CAPLUS  
DOCUMENT NUMBER: 132:179381  
TITLE: Hepatitis C virus infection: immune  
responsiveness and interferon-.alpha.  
treatment  
AUTHOR(S): Jirillo, E.; Pellegrino, N. M.; Piazzolla, G.;  
Caccavo, D.; Antonaci, S.  
CORPORATE SOURCE: Department of "Clinical Medicine, Immunology and  
Infectious Disease", University of Bari, Bari, Italy  
SOURCE: Current Pharmaceutical Design (2000), 6(2), 169-180  
CODEN: CPDEFP; ISSN: 1381-6128  
PUBLISHER: Bentham Science Publishers  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English  
TI Hepatitis C virus infection: immune responsiveness and  
interferon-.alpha. treatment  
REFERENCE COUNT: 132 THERE ARE 132 CITED REFERENCES  
AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L8 ANSWER 19 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1998:645414 CAPLUS

DOCUMENT NUMBER: 130:199  
 TITLE: The antiviral compound ribavirin modulates  
 the T helper (Th) 1/Th2 subset balance in  
 hepatitis B and C virus-specific immune  
 responses  
 AUTHOR(S): Hultgren, Catharina; Milich, David R.; Weiland, Ola;  
 Sallberg, Matti  
 CORPORATE SOURCE: Divisions of Clinical Virology, F 68, Oral  
 Microbiology, F 88, and Basic Oral Sciences, F 59,  
 Huddinge University Hospital, Huddinge, S-141 86,  
 Swed.  
 SOURCE: Journal of General Virology (1998), 79(10), 2381-2391  
 CODEN: JGVIAY; ISSN: 0022-1317  
 PUBLISHER: Society for General Microbiology  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 TI The antiviral compound ribavirin modulates the T helper (Th)  
 1/Th2 subset balance in hepatitis B and C virus-specific immune  
 responses  
 REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES  
 AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 20 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:13875 CAPLUS  
 DOCUMENT NUMBER: 128:85155  
 TITLE: Synthetic genes for hepatitis C virus  
 antigens for vaccine use  
 INVENTOR(S): Donnelly, John J.; Lu, Tong-Ming; Liu, Margaret A.;  
 Shiver, John W.  
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
 SOURCE: PCT Int. Appl., 51 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9747358	A1	19971218	WO 1997-US9884	19970606
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB,				



GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,  
ML, MR, NE, SN, TD, TG

CA 2257137 AA 19971218 CA 1997-2257137 19970606

AU 9733808 A1 19980107 AU 1997-33808 19970606

AU 717542 B2 20000330

EP 1009763 A1 20000621 EP 1997-929842 19970606

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI

JP 2002500502 T2 20020108 JP 1998-501722 19970606

US 2003053987 A1 20030320 US 2000-194949 20000217

US 6653125 B2 20031125

US 2005074752 A1 20050407 US 2003-664391 20030917

PRIORITY APPLN. INFO.: US 1996-20494P P 19960611

GB 1996-14731 A 19960712

US 1996-33534P P 19961220

WO 1997-US9884 W 19970606

US 2000-194949 A1 20000217

TI Synthetic genes for hepatitis C virus antigens for vaccine use

L8 ANSWER 21 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION-NUMBER: 1997:796986 CAPLUS

DOCUMENT NUMBER: 128:100793

TITLE: Current therapeutic trends in therapy for chronic  
viral hepatitis

AUTHOR(S): Liaw, Yun-Fan

CORPORATE SOURCE: Liver Res. Unit, Chang Gung Memorial Hosp., Chang  
Gung

Med. Coll., Taipei, Taiwan

SOURCE: Journal of Gastroenterology and Hepatology (1997),  
12(9/10), S346-S353

CODEN: JGHEEO; ISSN: 0815-9319

PUBLISHER: Blackwell Science Pty Ltd.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

TI Current therapeutic trends in therapy for chronic viral hepatitis

REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 22 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2006:79991 BIOSIS

DOCUMENT NUMBER: PREV200600086732

TITLE: Clinical value of total HCV core antigen  
detection and quantification.

AUTHOR(S): Omar, Mahmoud M.; Abdel-Aziz, Ayman; Abdel-Aziz, Eman;

SOURCE: Mohamed, Laila; Abu-Madian, Abroad  
Gastroenterology, (APR 2004) Vol. 126, No. 4, Suppl. 2, pp.  
A746.

Meeting Info.: Digestive Disease Week/105th Annual Meeting  
of the American-Gastroenterological-Association. New  
Orleans, LA, USA. May 16 -20, 2004. Amer Gastroenterol  
Assoc.

CODEN: GASTAB. ISSN: 0016-5085.

DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 25 Jan 2006

Last Updated on STN: 25 Jan 2006

TI Clinical value of total HCV core antigen detection and  
quantification.

L8 ANSWER 23 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2005:516763 BIOSIS

DOCUMENT NUMBER: PREV200510305433

TITLE: Leucocytophoresis with Adacolumn (R) enhances HCV-specific  
proliferative responses in patients infected with  
hepatitis C virus genotype 1.

AUTHOR(S): Diepolder, Helmut M.; Kashiwagi, Nobuhito; Teuber,  
Gerlinde; Ulsenheimer, Axel; Franz, Marita [Reprint  
Author]; Yokoyama, Takashi; Zachoval, Reinhart

CORPORATE SOURCE: Otsuka Frankfurt Res Inst GmbH, Grueneburgweg 102, D-  
60323

Frankfurt, Germany  
mfranz@otsuka.de

SOURCE: Journal of Medical Virology, (OCT 2005) Vol. 77, No. 2, pp.  
209-215.

CODEN: JMVIDB. ISSN: 0146-6615.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 23 Nov 2005

Last Updated on STN: 23 Nov 2005

TI Leucocytophoresis with Adacolumn (R) enhances HCV-specific proliferative  
responses in patients infected with hepatitis C virus genotype  
1.

L8 ANSWER 24 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2005:357005 BIOSIS

DOCUMENT NUMBER: PREV200510148172  
TITLE: Baseline HCV core antigen/HCV RNA  
ratio: Association with treatment responses.  
AUTHOR(S): Pradat, Pierre [Reprint Author]; Maynard, Marianne;  
Berthillon, Pascale; Bailly, Francois; Bordes, Isabelle;  
Tillmann, Hans L.; Trepo, Christian  
CORPORATE SOURCE: Hop Hotel Dieu, Lyon, France  
SOURCE: Hepatology, (OCT 2004) Vol. 40, No. 4, Suppl. 1, pp. 326A.  
Meeting Info.: 55th Annual Meeting of the  
American-Association-for-the-Study-of-Liver-Diseases  
(AASLD). Boston, MA, USA. October 29 -November 02, 2004.  
Amer Assoc Study Liver Dis.  
CODEN: HPTLD9. ISSN: 0270-9139.  
DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
LANGUAGE: English  
ENTRY DATE: Entered STN: 14 Sep 2005  
Last Updated on STN: 14 Sep 2005  
TI Baseline HCV core antigen/HCV RNA ratio: Association  
with treatment responses.

L8 ANSWER 25 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2005:73895 BIOSIS  
DOCUMENT NUMBER: PREV200500075326  
TITLE: Comparison of hepatitis C viral RNA and  
core antigen kinetics in the therapeutic  
follow up of hepatitis C virus and human  
immunodeficiency virus co-infected patients, treated by  
bitherapy interferon-ribavirin, within the  
framework of RIBAVIC protocol.  
Original Title: Comparaison des cinetiques de l' ARN et de  
l'antigene de capside du virus de l'hepatite C dans le  
suivi therapeutique des patients co-infectes par le virus  
de l'hepatite C et le virus de l'immunodeficiencie humaine,  
traites par bitherapie interferon-ribavirine, dans le cadre  
du protocole RIBAVIC.  
AUTHOR(S): Pivert, A. [Reprint Author]; Payan, C.; Lunel, F  
CORPORATE SOURCE: Lab Bacteriol Virol Hyg Hospitaliere, CHU Angers, Angers,  
France  
adeline.pivert@caramail.com  
SOURCE: Pathologie Biologie, (November 2004) Vol. 52, No. 9, pp.  
522-528. print.  
ISSN: 0369-8114 (ISSN print).  
DOCUMENT TYPE: Article

LANGUAGE: French  
ENTRY DATE: Entered STN: 16 Feb 2005  
Last Updated on STN: 16 Feb 2005

TI Comparison of hepatitis C viral RNA and core antigen kinetics in the therapeutic follow up of hepatitis C virus and human immunodeficiency virus co-infected patients, treated by bitherapy interferon-ribavirin, within the framework of RIBAVIC protocol.

Original Title: Comparaison des cinetiques de l' ARN et de l'antigene de capside du virus de l'hepatite C dans le suivi therapeutique des patients co-infectes par le virus de l'hepatite C et le virus de l'immunodeficienne humaine, traites par bitherapie interferon-ribavirine, dans le cadre du protocole RIBAVIC.

L8 ANSWER 26 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on  
STN

ACCESSION NUMBER: 2004:417575 BIOSIS

DOCUMENT NUMBER: PREV200400418431

TITLE: Serum levels of hepatitis C virus core antigen as a marker of infection and response to therapy.

AUTHOR(S): Soffredini, Roberta; Rumi, Maria Grazia; Parravicini, Maria Luisa; Ronchi, Guido; Del Ninno, Ersilio; Russo, Antonio; Colombo, Massimo [Reprint Author]

CORPORATE SOURCE: Div HepatolDept Gastroenterol and EndocrinolAM  
Migliavacca

Ctr Liver Dis, IRCCS Maggiore Hosp, Via PAce 9, I-20122,  
Milan, Italy

SOURCE: American Journal of Gastroenterology, (September 2004) Vol. 99, No. 9, pp. 1738-1743. print.  
ISSN: 0002-9270 (ISSN print).

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 27 Oct 2004  
Last Updated on STN: 27 Oct 2004

TI Serum levels of hepatitis C virus core antigen as a marker of infection and response to therapy.

L8 ANSWER 27 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on  
STN

ACCESSION NUMBER: 2004:334042 BIOSIS

DOCUMENT NUMBER: PREV200400334828

TITLE: Sequential changes of hepatitis C virus antibody profiles during treatment of chronic

hepatitis C of genotype 1b: Pretreatment antibody  
response to E2/NS1 correlated sustained response.

AUTHOR(S): Chu, C. M. [Reprint Author]; Sheen, I. S.; Liaw, Y. F.  
CORPORATE SOURCE: Liver Res Unit, Chang Gung Mem Hosp, 199 Tung Hwa N  
Rd,

Taipei, 105, Taiwan  
chuoo66@cgmh.org.tw

SOURCE: Infection, (June 2004) Vol. 32, No. 3, pp. 153-156. print.  
CODEN: IFTNAL. ISSN: 0300-8126.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 4 Aug 2004

Last Updated on STN: 4 Aug 2004

TI Sequential changes of hepatitis C virus antibody profiles during  
treatment of chronic hepatitis C of genotype 1b:  
Pretreatment antibody response to E2/NS1 correlated sustained response.

L8 ANSWER 28 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2004:325700 BIOSIS

DOCUMENT NUMBER: PREV200400327000

TITLE: The predictive value of core antigen  
testing for the management of hepatitis C  
patients receiving pegylated interferon/ribavirin  
treatment.

AUTHOR(S): Pradat, Pierre [Reprint Author]; Maynard, Marianne; Buti,  
Maria; Berthillon, Pascale; Picchio, Gaston; Tillmann, Hans  
L.; Wiegand, Johannes; Voirin, Nicolas; Manns, Michael P.;  
Esteban, Juan-Ignacio; Martinot, Michele; Marcellin,  
Patrick; Trepo, Christian

CORPORATE SOURCE: Dept Hepatol, Hop Hotel Dieu, 1,Pl Hop, F-69288, Lyon, 02,  
France  
pradat@univ-lyon1.fr

SOURCE: Journal of Medical Virology, (July 2004) Vol. 73, No. 3,  
pp. 392-396. print.  
CODEN: JMVIDB. ISSN: 0146-6615.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 29 Jul 2004

Last Updated on STN: 29 Jul 2004

TI The predictive value of core antigen testing for the  
management of hepatitis C patients receiving pegylated  
interferon/ribavirin treatment.

L8 ANSWER 29 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2004:225592 BIOSIS

DOCUMENT NUMBER: PREV200400226531

TITLE: Hepatitis C virus Core Antigen  
as a predictor of non-response in genotype 1 chronic  
hepatitis C patients treated with peginterferon  
alpha-2b plus ribavirin.

AUTHOR(S): Buti, Maria [Reprint Author]; Mendez, Claudia; Schaper,  
Melanie; Sauleda, Silvia; Valdes, Auristela;  
Rodriguez-Frias, Francisco; Jardi, Rosendo; Esteban, Rafael

CORPORATE SOURCE: Liver Unit, Hospital General Universitari Vall d'Hebron,  
Paseo Valle de Hebron 119, Barcelona, 08035, Spain  
mbuti@vhebron.net

SOURCE: Journal of Hepatology, (March 2004) Vol. 40, No. 3, pp.  
527-532. print.  
ISSN: 0168-8278 (ISSN print).

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 21 Apr 2004  
Last Updated on STN: 21 Apr 2004

TI Hepatitis C virus Core Antigen as a  
predictor of non-response in genotype 1 chronic hepatitis C  
patients treated with peginterferon alpha-2b plus ribavirin.

L8 ANSWER 30 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2004:180583 BIOSIS

DOCUMENT NUMBER: PREV200400180766

TITLE: Fatal cryptogenic liver disease after sustained eradication  
of recurrent hepatitic C in liver transplantation.

AUTHOR(S): Mukherjee, Sandeep [Reprint Author]; Gilroy, Richard K.  
[Reprint Author]; Rogge, Joyce [Reprint Author]; Weaver,  
Lynne [Reprint Author]; McCashland, Timothy M. [Reprint  
Author]; Schafer, Daniel F. [Reprint Author]

CORPORATE SOURCE: University of Nebraska Medical Center, Omaha, NE, USA

SOURCE: Hepatology, (October 2003) Vol. 38, No. 4 Suppl. 1, pp.  
526A-527A. print.

Meeting Info.: 54th Annual Meeting of the American  
Association for the Study of Liver Diseases. Boston, MA,  
USA. October 24-28, 2003. American Association for the  
Study of Liver Diseases.

ISSN: 0270-9139 (ISSN print).

DOCUMENT TYPE: Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)  
LANGUAGE: English  
ENTRY DATE: Entered STN: 7 Apr-2004  
Last Updated on STN: 7 Apr 2004  
TI Fatal cryptogenic liver disease after sustained eradication of recurrent  
hepatitic C in liver transplantation.

L8 ANSWER 31 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN  
ACCESSION NUMBER: 2004:133624 BIOSIS  
DOCUMENT NUMBER: PREV200400132084  
TITLE: Total HCV core antigen correlates with  
HCV RNA, and predicts response to peginterferon alfa 2-a  
(PEG-IFN) and ribavirin (Rib) therapy in chronic  
hepatitis C.

AUTHOR(S): Padilla, Eduardo [Reprint Author]; Planas, Ramon [Reprint  
Author]; Gonzalez, Vicky [Reprint Author]; Perez, Celia;  
Gimenez, Dolores; Matas, Lourdes [Reprint Author]; Morillas,  
Rosa Maria [Reprint Author]; Cabre, Eduard [Reprint  
Author]; Sola, Ricard; Diago, Moises; Ausina, Vicens  
[Reprint Author]

CORPORATE SOURCE: Hospital Germans Trias i Pujol, Badalona, Spain  
SOURCE: Hepatology, (October 2003) Vol. 38, No. 4 Suppl. 1, pp.  
626A. print.  
Meeting Info.: 54th Annual Meeting of the American  
Association for the Study of Liver Diseases. Boston, MA,  
USA. October 24-28, 2003. American Association for the  
Study of Liver Diseases.  
ISSN: 0270-9139 (ISSN print).

DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)

LANGUAGE: English  
ENTRY DATE: Entered STN: 10 Mar 2004  
Last Updated on STN: 10 Mar 2004

TI Total HCV core antigen correlates with HCV RNA, and  
predicts response to peginterferon alfa 2-a (PEG-IFN) and  
ribavirin (Rib) therapy in chronic hepatitis C.

L8 ANSWER 32 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN  
ACCESSION NUMBER: 2004:124070 BIOSIS  
DOCUMENT NUMBER: PREV200400116984  
TITLE: Monitoring HCV core antigen during  
antiviral therapy.

AUTHOR(S): Di Bisceglie, Adrian M. [Reprint Author]; Strinko, Janice  
[Reprint Author]; Osmack, Patricia [Reprint Author]  
CORPORATE SOURCE: Saint Louis University Health Sciences Center, Saint Louis,  
MO, USA  
SOURCE: Hepatology, (October 2003) Vol. 38, No. 4 Suppl. 1, pp.  
430A-431A. print.  
Meeting Info.: 54th Annual Meeting of the American  
Association for the Study of Liver Diseases. Boston, MA,  
USA. October 24-28, 2003. American Association for the  
Study of Liver Diseases.  
ISSN: 0270-9139 (ISSN print).  
DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
LANGUAGE: English  
ENTRY DATE: Entered STN: 3 Mar 2004  
Last Updated on STN: 3 Mar 2004  
TI Monitoring HCV core antigen during antiviral therapy.

L8 ANSWER 33 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on  
STN

ACCESSION NUMBER: 2004:123681 BIOSIS  
DOCUMENT NUMBER: PREV200400116810  
TITLE: Pharmacodynamics and pharmacokinetics of hepatitis  
C virus (HCV) and pegylated interferon-alfa2b in human  
immunodeficiency virus (HIV)/HCV co-infected patients.  
AUTHOR(S): Golia, Preeti [Reprint Author]; Powers, Kimberly; Dorante,  
Gary [Reprint Author]; Cunningham-Rundles, Susanna [Reprint  
Author]; Ribeiro, Ruy; Shata, Mohammed T.; Perelson, Alan  
S.; Talal, Andrew H. [Reprint Author]  
CORPORATE SOURCE: Weill Medical College of Cornell University, New York, NY,  
USA  
SOURCE: Hepatology, (October 2003) Vol. 38, No. 4 Suppl. 1, pp.  
345A. print.  
Meeting Info.: 54th Annual Meeting of the American  
Association for the Study of Liver Diseases. Boston, MA,  
USA. October 24-28, 2003. American Association for the  
Study of Liver Diseases.  
ISSN: 0270-9139 (ISSN print).  
DOCUMENT TYPE: Conference; (Meeting)  
Conference; (Meeting Poster)  
Conference; Abstract; (Meeting Abstract)  
LANGUAGE: English  
ENTRY DATE: Entered STN: 3 Mar 2004  
Last Updated on STN: 3 Mar 2004  
TI Pharmacodynamics and pharmacokinetics of hepatitis C virus (HCV)



and pegylated interferon-alfa2b in human immunodeficiency virus (HIV)/HCV co-infected patients.

L8 ANSWER 34 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2004:84389 BIOSIS

DOCUMENT NUMBER: PREV200400087046

TITLE: Antiviral effect of ribavirin in early  
non-responders to interferon monotherapy assessed by  
kinetics of hepatitis C virus RNA and  
hepatitis C virus core antigen.

AUTHOR(S): Lunel, Françoise [Reprint Author]; Veillon, Pascal;  
Fouchard-Hubert, Isabelle; Loustaud-Ratti, Veronique;  
Abergel, Armand; Silvain, Christine; Rifflet, Herve;  
Blanchi, Alain; Causse, Xavier; Bacq, Yannick; Payan,  
Christopher

CORPORATE SOURCE: Laboratoire de Bacteriologie-Virologie, CHU Angers, 4 rue  
Larrey, 49033, Angers Cedex, France  
frlunel-fabiani@chu-angers.fr

SOURCE: Journal of Hepatology, (November 2003) Vol. 39, No. 5, pp.  
826-833. print.  
ISSN: 0168-8278 (ISSN print).

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 11 Feb 2004

Last Updated on STN: 11 Feb 2004

TI Antiviral effect of ribavirin in early non-responders to  
interferon monotherapy assessed by kinetics of hepatitis C virus  
RNA and hepatitis C virus core antigen.

L8 ANSWER 35 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2004:47847 BIOSIS

DOCUMENT NUMBER: PREV200400050095

TITLE: Total HCV core antigen assay: A  
surrogate marker of viral replication and its use in  
monitoring response to therapy.

AUTHOR(S): Trepo, Christian [Reprint Author]; Marcellin, Patrick;  
Zanetti, Alessandro; Lunel-Fabiani, Françoise

CORPORATE SOURCE: INSERM, Lyon, France

SOURCE: Journal of Hepatology, (April 2002) Vol. 36, No. Supplement  
1, pp. 134. print.  
Meeting Info.: Biennial Meeting of the International  
Association for the Study of the Liver. Madrid, Spain.

April 15-16, 2002. European Association for the Study of the Liver; International Association for the Study of the Liver.

ISSN: 0168-8278 (ISSN print).

DOCUMENT TYPE: Conference; (Meeting)  
Conference; (Meeting Poster)  
Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 21 Jan 2004

Last Updated on STN: 21 Jan 2004

TI Total HCV core antigen assay: A surrogate marker of viral replication and it's use in monitoring response to therapy.

L8 ANSWER 36 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2004:31890 BIOSIS

DOCUMENT NUMBER: PREV200400033934

TITLE: Evaluation of ortho Total HCV core antigen assay in assessment and follow up of patients treated for chronic HCV.

AUTHOR(S): Lunel, Françoise [Reprint Author]; Veillon, Pascal [Reprint Author]; Payan, Christopher [Reprint Author]

CORPORATE SOURCE: Laboratoire de Bacterio-Virologie, Angers, France

SOURCE: Journal of Hepatology, (April 2002) Vol. 36, No. Supplement 1, pp. 90. print.

Meeting Info.: Biennial Meeting of the International

Association for the Study of the Liver. Madrid, Spain.

April 15-16, 2002. European Association for the Study of the Liver; International Association for the Study of the Liver.

ISSN: 0168-8278 (ISSN print).

DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 7 Jan 2004

Last Updated on STN: 7 Jan 2004

TI Evaluation of ortho Total HCV core antigen assay in assessment and follow up of patients treated for chronic HCV.

L8 ANSWER 37 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2004:31889 BIOSIS

DOCUMENT NUMBER: PREV200400033933

TITLE: Ortho Total HCV Core Antigen Assay can

aid early prediction of response in patients treated with  
interferon/ribavirin.

AUTHOR(S): Lunel, Francoise [Reprint Author]; Veillon, Pascal [Reprint  
Author]; Payan, Christopher [Reprint Author]  
CORPORATE SOURCE: Laboratoire de Bacterio-Virologie, CHU Angers, Angers,  
France  
SOURCE: Journal of Hepatology, (April 2002) Vol. 36, No. Supplement  
1, pp. 90. print.  
Meeting Info.: Biennial Meeting of the International  
Association for the Study of the Liver. Madrid, Spain.  
April 15-16, 2002. European Association for the Study of  
the Liver; International Association for the Study of the  
Liver.  
ISSN: 0168-8278 (ISSN print).  
DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
LANGUAGE: English  
ENTRY DATE: Entered STN: 7 Jan 2004  
Last Updated on STN: 7 Jan 2004  
TI Ortho Total HCV Core Antigen Assay can aid early  
prediction of response in patients treated with interferon/  
ribavirin.

L8 ANSWER 38 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on  
STN

ACCESSION NUMBER: 2004:31888 BIOSIS  
DOCUMENT NUMBER: PREV200400033932  
TITLE: Quantitative determination of hepatitis C virus  
core antigen (HCVAg) and prediction of  
response to therapy in chronic HCV infection.  
AUTHOR(S): Jacobs, Ruth [Reprint Author]; Brown, David; Diment, John;  
Whitehe, Josephine; Dusheiko, Geoffrey  
CORPORATE SOURCE: Centre for Hepatology, Medical School, Royal Free and  
University College, London, NW3 2PF, UK  
SOURCE: Journal of Hepatology, (April 2002) Vol. 36, No. Supplement  
1, pp. 90. print.  
Meeting Info.: Biennial Meeting of the International  
Association for the Study of the Liver. Madrid, Spain.  
April 15-16, 2002. European Association for the Study of  
the Liver; International Association for the Study of the  
Liver.  
ISSN: 0168-8278 (ISSN print).  
DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
LANGUAGE: English

ENTRY DATE: Entered STN: 7 Jan 2004

Last Updated on STN: 7 Jan 2004

TI Quantitative determination of hepatitis C virus core antigen (HCVAg) and prediction of response to therapy in chronic HCV infection.

L8 ANSWER 39 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2004:14175 BIOSIS

DOCUMENT NUMBER: PREV200400015835

TITLE: Comparison of HCV RNA and HCV core antigen kinetics in the follow up of a therapeutic protocol in HCV-HIV co-infected patients (Ribavir).

AUTHOR(S): Fabiani, F. Lunel [Reprint Author]; Pivert, A. [Reprint Author]; Payan, C. [Reprint Author]; RIBAVIC Scientific Committee (Attempt ANRS HC02) [Reprint Author]

CORPORATE SOURCE: Laboratoire de Bacteriologie Virologie, CHU Angers, Angers,

France

SOURCE: Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, (2003) Vol. 43, pp. 503. print.  
Meeting Info.: 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA. September 14-17, 2003. American Society for Microbiology.

DOCUMENT TYPE: Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 24 Dec 2003

Last Updated on STN: 24 Dec 2003

TI Comparison of HCV RNA and HCV core antigen kinetics in the follow up of a therapeutic protocol in HCV-HIV co-infected patients (Ribavir).

L8 ANSWER 40 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2004:14174 BIOSIS

DOCUMENT NUMBER: PREV200400015834

TITLE: Antiviral effect of Ribavirin in early non-responders to interferon monotherapy assessed by kinetics of Hepatitis C virus RNA and HCV Core antigen.

AUTHOR(S): Veillon, P. [Reprint Author]; Payan, C. [Reprint Author]; Fouchard-Hubert, I.; Loustaud-Ratti, V.; Lunel-Fabiani, F. [Reprint Author]; Fontevraud Study Group

CORPORATE SOURCE: Laboratoire de Bacterio-Virologie, CHU Angers, Angers, France

SOURCE: Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, (2003) Vol. 43, pp. 503. print.  
Meeting Info.: 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA. September 14-17, 2003. American Society for Microbiology.

DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 24 Dec 2003

Last Updated on STN: 24 Dec 2003

TI Antiviral effect of Ribavirin in early non-responders to interferon monotherapy assessed by kinetics of Hepatitis C virus RNA and HCV Core antigen.

L8 ANSWER 41 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2003:328340 BIOSIS

DOCUMENT NUMBER: PREV200300328340

TITLE: Hepatitis C virus RNA and HCV Core antigen kinetics predict the efficiency of alfa-interferon and ribavirin therapy in naive patients infected by hepatitis C virus genotype 2 or 3.

AUTHOR(S): Lunel, F. [Reprint Author]; Veillon, P. [Reprint Author]; Payan, C. [Reprint Author]; Fontevraud Study Group [Reprint Author]

CORPORATE SOURCE: CHU Angers, Angers, France

SOURCE: Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, (2002) Vol. 42, pp. 426. print.  
Meeting Info.: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA. September 27-30, 2002. American Society for Microbiology.

DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 16 Jul 2003

Last Updated on STN: 16 Jul 2003

TI Hepatitis C virus RNA and HCV Core antigen kinetics predict the efficiency of alfa-interferon and ribavirin therapy in naive patients infected by hepatitis C virus genotype 2 or 3.

L8 ANSWER 42 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2003:247888 BIOSIS

DOCUMENT NUMBER: PREV200300247888

TITLE: Concomitant augmentation of type 1 CD4+ and CD8+ T-cell  
responses during successful interferon-alpha and  
ribavirin treatment for chronic  
hepatitis C virus infection.

AUTHOR(S): Sreenarasimhaiah, Jayaprakash; Jaramillo, Andres; Crippin,  
Jeffrey; Lisker-Melman, Mauricio; Chapman, William C.;  
Mohanakumar, T. [Reprint Author]

CORPORATE SOURCE: Department of Surgery, Washington University School of  
Medicine, 660 South Euclid Avenue, CSRB.3328, Box 8109,  
Saint Louis, MO, 63110, USA  
kumart@msnotes.wustl.edu

SOURCE: Human Immunology, (May 2003) Vol. 64, No. 5, pp. 497-504.  
print.

CODEN: HUIMDQ. ISSN: 0198-8859.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 21 May 2003

Last Updated on STN: 21 May 2003

TI Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during  
successful interferon-alpha and ribavirin treatment  
for chronic hepatitis C virus infection.

L8 ANSWER 43 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2002:631542 BIOSIS

DOCUMENT NUMBER: PREV200200631542

TITLE: Ribavirin increases mitogen- and antigen-induced  
expression of CD40L on CD4+ T cells in vivo.

AUTHOR(S): Bergamini, A. [Reprint author]; Cepparulo, M.; Bolacchi,  
F.; Araco, A.; Tisone, G.; Ombres, D.; Rocchi, G.;  
Angelico, M.

CORPORATE SOURCE: Dipartimento di Sanita Pubblica e Biologia Cellulare,  
Cattedra di Malattie Infettive, Universita di Roma 'Tor  
Vergata', Via di Tor Vergata 135, 00133, Roma, Italy  
bergamini@med.uniroma2.it

SOURCE: Clinical and Experimental Immunology, (November, 2002) Vol.  
130, No. 2, pp. 293-299. print.

CODEN: CEXIAL. ISSN: 0009-9104.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 12 Dec 2002

Last Updated on STN: 12 Dec 2002

TI Ribavirin increases mitogen- and antigen-induced expression of  
CD40L on CD4+ T cells in vivo.

L8 ANSWER 44 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2002:618359 BIOSIS

DOCUMENT NUMBER: PREV200200618359

TITLE: Hepatitis C core antigen  
response to treatment with pegylated interferon  
and ribavirin.

AUTHOR(S): Zacks, Steven [Reprint author]; Peace-Brewer, Amy [Reprint  
author]; Orton, Susan [Reprint author]; Theodore, Dickens  
[Reprint author]; Pusek, Susan [Reprint author]; Shrestha,  
Roshan [Reprint author]; Fried, Michael W. [Reprint author]

CORPORATE SOURCE: University of North Carolina at Chapel Hill, Chapel Hill,  
NC, USA

SOURCE: Hepatology, (October, 2002) Vol. 36, No. 4 Part 2, pp.  
356A. print.

Meeting Info.: 53rd Annual Meeting on the Liver. BOSTON,  
MA, USA. November 01-05, 2002.

CODEN: HPTLD9. ISSN: 0270-9139.

DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 4 Dec 2002

Last Updated on STN: 4 Dec 2002

TI Hepatitis C core antigen response to  
treatment with pegylated interferon and ribavirin.

L8 ANSWER 45 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2002:463894 BIOSIS

DOCUMENT NUMBER: PREV200200463894

TITLE: CD4 T lymphocyte proliferative responses to  
hepatitis C virus (HCV) antigens in patients  
coinfectd with HCV and human immunodeficiency virus who  
responded to anti-HCV treatment.

AUTHOR(S): Legrand, Elisabeth; Neau, Didier [Reprint author];  
Galperine, Tatiana; Trimoulet, Pascale; Moreau,  
Jean-Francois; Pitard, Vincent; Lacut, Jean-Yves; Ragnaud,  
Jean-Marie; Dupon, Michel; Le Bail, Brigitte; Bernard,  
Noelle; Schvoerer, Evelyne; Houghton, Michael; Fleury,

Herve; Lafon, Marie-Edith  
CORPORATE SOURCE: Federation de Maladies Infectieuses, Hopital Pellegrin,  
Place Amelie Raba Leon, 33076, Bordeaux cedex, France  
didier.neau@chu-bordeaux.fr  
SOURCE: Journal of Infectious Diseases, (1 August, 2002) Vol. 186,  
No. 3, pp. 302-311. print.  
CODEN: JIDIAQ. ISSN: 0022-1899.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
ENTRY DATE: Entered STN: 28 Aug 2002  
Last Updated on STN: 28 Aug 2002  
TI CD4 T lymphocyte proliferative responses to hepatitis C virus  
(HCV) antigens in patients coinfectd with HCV and human immunodeficiency  
virus who responded to anti-HCV treatment.

L8 ANSWER 46 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on  
STN  
ACCESSION NUMBER: 2002:76839 BIOSIS  
DOCUMENT NUMBER: PREV200200076839  
TITLE: Ribavirin enhances interferon-gamma levels in  
patients with chronic hepatitis C treated with  
interferon-alpha.  
AUTHOR(S): Fang, Shih-Hua; Lai, Ming-Yang; Hwang, Lih-Hwa; Yang,  
Pei-Ming; Chen, Pei-Jer; Chiang, Bor-Luen [Reprint author];  
Chen, Ding-Shinn  
CORPORATE SOURCE: Graduate Institute of Clinical Medicine, College of  
Medicine, National Taiwan University, No. 1, Chang-Teh  
Street, Taipei, 100, Taiwan  
gicmbor@ha.mc.ntu.edu.tw  
SOURCE: Journal of Biomedical Science, (November-December, 2001)  
Vol. 8, No. 6, pp. 484-491. print.  
ISSN: 1021-7770.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
ENTRY DATE: Entered STN: 16 Jan 2002  
Last Updated on STN: 25 Feb 2002  
TI Ribavirin enhances interferon-gamma levels in patients with  
chronic hepatitis C treated with interferon-alpha.

L8 ANSWER 47 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on  
STN  
ACCESSION NUMBER: 2001:528598 BIOSIS  
DOCUMENT NUMBER: PREV200100528598  
TITLE: Hepatitis C virus (HCV) core



antigen kinetics during treatment of  
chronic hepatitis C with interferon alpha and/or  
ribavirin.

AUTHOR(S): Dahari, Harel [Reprint author]; Hezode, Christophe;  
Bouvier-Alias, Magali; Dhumeaux, Daniel; Neumann, Avidan  
U.; Pawlotsky, Jean-Michel

CORPORATE SOURCE: Bar-Ilan Univ, Bar-Ilan, Israel

SOURCE: Hepatology, (October, 2001) Vol. 34, No. 4 Pt. 2, pp. 217A.  
print.

Meeting Info.: 52nd Annual Meeting and Postgraduate Courses  
of the American Association for the Study of Liver  
Diseases. Dallas, Texas, USA. November 09-13, 2001.

CODEN: HPTLD9. ISSN: 0270-9139.

DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 14 Nov 2001

Last Updated on STN: 23 Feb 2002

TI Hepatitis C virus (HCV) core antigen  
kinetics during treatment of chronic hepatitis C with  
interferon alpha and/or ribavirin.

L8 ANSWER 48 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 2001:52853 BIOSIS

DOCUMENT NUMBER: PREV200100052853

TITLE: Hepatitis B virus-specific T-cell proliferation  
and cytokine secretion in chronic hepatitis B e  
antibody-positive patients treated with ribavirin  
and interferon alfa.

AUTHOR(S): Rico, Miguel A.; Quiroga, Juan Antonio; Subira, Dolores;  
Castanon, Susana; Esteban, Jose Miguel; Pardo, Margarita;  
Carreno, Vicente [Reprint author]

CORPORATE SOURCE: Fundacion para el Estudio de las Hepatitis Virales, C/  
Guzman el Bueno, 72, 28015, Madrid, Spain  
fehv@tdi.es

SOURCE: Hepatology, (January, 2001) Vol. 33, No. 1, pp. 295-300.  
print.

CODEN: HPTLD9. ISSN: 0270-9139.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 24 Jan 2001

Last Updated on STN: 12 Feb 2002

TI Hepatitis B virus-specific T-cell proliferation and cytokine  
secretion in chronic hepatitis B e antibody-positive patients

treated with ribavirin and interferon alfa.

L8 ANSWER 49 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 1998:49224 BIOSIS

DOCUMENT NUMBER: PREV199800049224

TITLE: Current therapeutic trends in therapy for chronic viral  
hepatitis.

AUTHOR(S): Liaw, Yun-Fan [Reprint author]

CORPORATE SOURCE: Liver Res. Unit, Chang Gung Memorial Hosp., 199 Tung  
Hwa

North Rd., Taipei 105, Taiwan

SOURCE: Journal of Gastroenterology and Hepatology, (Oct., 1997)

Vol. 12, No. 9-10, pp. S346-S353. print.

CODEN: JGHEEO. ISSN: 0815-9319.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 27 Jan 1998

Last Updated on STN: 27 Jan 1998

TI Current therapeutic trends in therapy for chronic viral hepatitis

L8 ANSWER 50 OF 50 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on

STN

ACCESSION NUMBER: 1995:486510 BIOSIS

DOCUMENT NUMBER: PREV199598500810

TITLE: Current treatment of chronic viral  
hepatitis.

AUTHOR(S): Blum, H. E. [Reprint author]; Maier, K.-P.; Strohmeyer, G.

CORPORATE SOURCE: Abt. Innere Med. II, Med. Universitaetsklin., Hugstetter  
Str. 55, 79106 Freiburg, Germany

SOURCE: DMW (Deutsche Medizinische Wochenschrift), (1995) Vol. 120,  
No. 9, pp. 295-300.

CODEN: DDMWDF. ISSN: 0012-0472.

DOCUMENT TYPE: Article

General Review; (Literature Review)

LANGUAGE: German

ENTRY DATE: Entered STN: 9 Nov 1995

Last Updated on STN: 14 Dec 1995

TI Current treatment of chronic viral hepatitis.

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE TOTAL

	ENTRY	SESSION	
FULL ESTIMATED COST	165.20		165.41
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE			
TOTAL			

	ENTRY	SESSION	
CA SUBSCRIBER PRICE	-3.75		-3.75

FILE 'STNGUIDE' ENTERED AT 11:15:48 ON 01 AUG 2006  
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
 AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM  
 KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
 LAST RELOADED: Jul 28, 2006 (20060728/UP).

=> file caplus

	ENTRY	SESSION	SINCE FILE	TOTAL
COST IN U.S. DOLLARS				
FULL ESTIMATED COST	0.18			165.59
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE				
TOTAL				

	ENTRY	SESSION	
CA SUBSCRIBER PRICE	0.00		-3.75

FILE 'CAPLUS' ENTERED AT 11:17:27 ON 01 AUG 2006  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Aug 2006 VOL 145 ISS 6  
 FILE LAST UPDATED: 31 Jul 2006 (20060731/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> D history

(FILE 'HOME' ENTERED AT 11:01:51 ON 01 AUG 2006)

FILE 'CAPLUS, BIOSIS' ENTERED AT 11:02:29 ON 01 AUG 2006

L1	9273 RIBAVIRIN
L2	170111 HEPATITIS
L3	5953 L1 AND L2
L4	3816972 TREATMENT
L5	3828 L3 AND L4
L6	4755 CORE (W) ANTIGEN
L7	4074 NS3
L8	50 L5 AND L6
L9	100 L5 AND L7
L10	200628 HIV
L11	819 L10 AND L1
L12	514 L11 AND L4
L13	3028344 PATIENT
L14	436 L13 AND L12
L15	97450 ENVELOPE
L16	1 L15 AND L14
L17	3580 L1 (S) L2
L18	1611 L4 (S) L17
L19	12 L6 (P) L18
L20	18 L8 (P) L18
L21	609 L10 (P) L1
L22	1 L21 (P) L15

FILE 'STNGUIDE' ENTERED AT 11:15:48 ON 01 AUG 2006

FILE 'CAPLUS' ENTERED AT 11:17:27 ON 01 AUG 2006

=> L9 duplicate remove

MISSING OPERATOR L9 DUPLICATE

The search profile that was entered contains terms or  
nested terms that are not separated by a logical operator.

=> L9

L23 73 L5 AND L7

=> D L23 IBIB TI 1-73

L23 ANSWER 1 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:494221 CAPLUS

DOCUMENT NUMBER: 145:8396

TITLE: Preparation of nucleoside analogs for treating  
Hepatitis C and other Flaviviridae family  
viral infections

INVENTOR(S): Keicher, Jesse D.; Roberts, Christopher D.; Dyatkina,  
Natalia B.

PATENT ASSIGNEE(S): Genelabs Technologies, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 23 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006111311	A1	20060525	US 2005-280984	20051115
PRIORITY APPLN. INFO.:			US 2004-630453P	P 20041122
TI Preparation of nucleoside analogs for treating Hepatitis C and other Flaviviridae family viral infections				

L23 ANSWER 2 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:437603 CAPLUS

DOCUMENT NUMBER: 144:460801

TITLE: VX-950 dose forms and use for the treatment  
of hepatitis C virus infection

INVENTOR(S): Chu, Hui-May; Ette, Ene; McNair, Lindsay; Alam, John

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 69 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006050250	A2	20060511	WO 2005-US39240	20051031
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,				

SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,  
VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM

US 2006105978 A1 20060518 US 2005-264746 20051031  
PRIORITY APPLN. INFO.: US 2004-623542P P 20041029  
US 2005-679402P P 20050509  
US 2005-682091P P 20050517  
US 2005-722746P P 20050930

TI VX-950 dose forms and use for the treatment of hepatitis  
C virus infection

L23 ANSWER 3 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:316806 CAPLUS

DOCUMENT NUMBER: 144:331664

TITLE: Preparation of nucleoside analogs as antiviral agents  
for treating flaviviruses, pestiviruses and  
hepacivirus

INVENTOR(S): Sommadossi, Jean-Pierre; Gosselin, Gilles; Storer,  
Richard; Egan, James

PATENT ASSIGNEE(S): Idenix (Cayman) Limited, Cayman I.; Centre National de  
la Recherche Scientifique

SOURCE: PCT Int. Appl., 73 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006037028	A2	20060406	WO 2005-US34786	20050926
WO 2006037028	A3	20060713		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,  
LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,  
NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,  
SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,  
YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-613085P P 20040924

OTHER SOURCE(S): MARPAT 144:331664

TI Preparation of nucleoside analogs as antiviral agents for treating  
flaviviruses, pestiviruses and hepacivirus

L23 ANSWER 4 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:296019 CAPLUS

DOCUMENT NUMBER: 144:312290

TITLE: Preparation of nucleoside derivatives as antiviral,  
antitumor, and antidiabetic prodrug agents

INVENTOR(S): Reddy, Raja K.; Erion, Mark D.

PATENT ASSIGNEE(S): Metabasis Therapeutics, Inc., USA

SOURCE: PCT Int. Appl., 255 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2006033709	A2	20060330	WO 2005-US27235	20050729
---------------	----	----------	-----------------	----------

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,  
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,  
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,  
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,  
ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM

US 2005182252	A1	20050818	US 2004-903215	20040729
---------------	----	----------	----------------	----------

PRIORITY APPLN. INFO.: US 2004-903215 A 20040729

US 2005-652527P P 20050211

US 2004-544743P. P 20040213

OTHER SOURCE(S): MARPAT 144:312290

TI Preparation of nucleoside derivatives as antiviral, antitumor, and  
antidiabetic prodrug agents

L23 ANSWER 5 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:87672 CAPLUS

TITLE: Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection

AUTHOR(S): Graham, Camilla S.; Wells, Annalee; Liu, Tun; Sherman, Kenneth E.; Peters, Marion; Chung, Raymond T.; Bhan, Atul K.; Andersen, Janet; Koziel, Margaret James

CORPORATE SOURCE: Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

SOURCE: AIDS (Hagerstown, MD, United States) (2006), 20(3), 345-351  
CODEN: AIDSET; ISSN: 0269-9370

PUBLISHER: Lippincott Williams & Wilkins

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 6 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:75299 CAPLUS

DOCUMENT NUMBER: 144:143019

TITLE: Anti-NS4a and anti-NS5a antibody detection-based methods for predicting the efficacy or outcome of hepatitis C virus (HCV) therapy

INVENTOR(S): Leroux-Roels, Geert; Desombere, Isabelle

PATENT ASSIGNEE(S): Universiteit Gent, Belg.

SOURCE: PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2006007674	A1	20060126	WO 2005-BE118	20050718
---------------	----	----------	---------------	----------

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,



ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-588522P P 20040716

TI Anti-NS4a and anti-NS5a antibody detection-based methods for predicting  
the efficacy or outcome of hepatitis C virus (HCV) therapy

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE  
FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 7 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1319337 CAPLUS

DOCUMENT NUMBER: 144:324191

TITLE: In vitro anti-HCV activities of Saxifraga melanocentra  
and its related polyphenolic compounds

AUTHOR(S): Zuo, Guo-Ying; Li, Zheng-Quan; Chen, Li-Rong; Xu,  
Xiao-Jie

CORPORATE SOURCE: College of Chemistry and Molecular Engineering,  
Yashentang Nature Medicine Laboratory, Peking  
University, Beijing, Peop. Rep. China

SOURCE: Antiviral Chemistry & Chemotherapy (2005), 16(6),  
393-398

CODEN: ACCHEH; ISSN: 0956-3202

PUBLISHER: International Medical Press

DOCUMENT TYPE: Journal

LANGUAGE: English

TI In vitro anti-HCV activities of Saxifraga melanocentra and its related  
polyphenolic compounds

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 8 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1259562 CAPLUS

DOCUMENT NUMBER: 144:7095

TITLE: Preparation of prolyl peptides as inhibitors of  
hepatitis C virus NS3 serine  
protease

INVENTOR(S): Arasappan, Ashok; Njoroge, F. George; Girjavallabhan,  
Viyyoor Moopil

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 120 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2005113581	A1	20051201	WO 2005-US17401	20050518
---------------	----	----------	-----------------	----------

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005272663	A1	20051208	US 2005-132083	20050518
---------------	----	----------	----------------	----------

PRIORITY APPLN. INFO.: US 2004-573191P P 20040520

OTHER SOURCE(S): MARPAT 144:7095

TI Preparation of prolyl peptides as inhibitors of hepatitis C virus NS3 serine protease

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 9 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1160431 CAPLUS

DOCUMENT NUMBER: 143:404304

TITLE: Dissecting the interferon-induced inhibition of hepatitis C virus replication by using a novel host cell line

AUTHOR(S): Windisch, Marc P.; Frese, Michael; Kaul, Artur; Trippler, Martin; Lohmann, Volker; Bartenschlager, Ralf

CORPORATE SOURCE: Department of Molecular Virology, Hygiene Institute, University of Heidelberg, Heidelberg, D-69120, Germany

SOURCE: Journal of Virology (2005), 79(21), 13778-13793  
CODEN: JOVIAM; ISSN: 0022-538X

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Dissecting the interferon-induced inhibition of hepatitis C

virus replication by using a novel host cell line  
REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES  
AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 10 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2005:1071799 CAPLUS  
DOCUMENT NUMBER: 144:218886  
TITLE: Leucocytophoresis with Adacolumn enhances HCV-specific  
proliferative responses in patients infected with  
hepatitis C virus genotypes 1  
AUTHOR(S): Diepolder, Helmut M.; Kashiwagi, Nobuhito; Teuber,  
Gerlinde; Ulsenheimer, Axel; Franz, Marita; Yokoyama,  
Takashi; Zachoval, Reinhart  
CORPORATE SOURCE: Institute for Immunology, University of Munich,  
Germany  
SOURCE: Journal of Medical Virology (2005), 77(2), 209-215  
CODEN: JMVIDB; ISSN: 0146-6615  
PUBLISHER: Wiley-Liss, Inc.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI Leucocytophoresis with Adacolumn enhances HCV-specific proliferative  
responses in patients infected with hepatitis C virus genotypes  
1

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES  
AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 11 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2005:1026930 CAPLUS  
DOCUMENT NUMBER: 143:306549  
TITLE: Preparation of novel peptides as inhibitors of  
hepatitis C virus NS3 serine  
protease  
INVENTOR(S): Arasappan, Ashok; Njoroge, F. George; Padilla-Acevedo,  
Angela I.; Chen, Kevin X.; Bennett, Frank; Sannigrahi,  
Mousumi; Bogen, Stephane L.; Venkatraman, Srikanth;  
Jao, Edwin; Saksena, Anil K.; Girjavallabhan, Viyyoor  
M.  
PATENT ASSIGNEE(S): Schering Corporation, USA  
SOURCE: PCT Int. Appl., 223 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2005087725	A2	20050922	WO 2005-US5773	20050224
WO 2005087725	A3	20051027		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005245458 A1 20051103 US 2005-65531 20050224  
 PRIORITY APPLN. INFO.: US 2004-548535P P 20040227  
 OTHER SOURCE(S): MARPAT 143:306549  
 TI Preparation of novel peptides as inhibitors of hepatitis C virus NS3 serine protease

L23 ANSWER 12 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1004768 CAPLUS

DOCUMENT NUMBER: 143:306546

TITLE: Preparation of peptides as inhibitors of hepatitis C virus NS3 protease

INVENTOR(S): Bogen, Stephane L.; Pan, Weidong; Ruan, Sumei; Chen, Kevin X.; Arasappan, Ashok; Venkatraman, Srikanth; Nair, Latha G.; Sannigrahi, Mousumi; Bennett, Frank; Saksena, Anil K.; Njoroge, F. George; Girijavallabhan, Viyyoor M.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 570 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2005085275	A1	20050915	WO 2005-US6502	20050224
---------------	----	----------	----------------	----------

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,  
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,  
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,  
MR, NE, SN, TD, TG

US 2005267043 A1 20051201 US 2005-65572 20050224  
PRIORITY APPLN. INFO.: US 2004-548251P P 20040227  
OTHER SOURCE(S): MARPAT 143:306546

TI Preparation of peptides as inhibitors of hepatitis C virus

NS3 protease

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE  
FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 13 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1004741 CAPLUS

DOCUMENT NUMBER: 143:306545

TITLE: Preparation of novel peptidyl ketoamides with cyclic  
p4s as inhibitors of NS3 serine protease of  
hepatitis C virus

INVENTOR(S): Chen, Kevin X.; Njoroge, F. George; Sannigrahi,  
Mousumi; Nair, Latha G.; Yang, Weiyang; Vibulbhan,  
Bancha; Venkatraman, Srikanth; Arasappan, Ashok;  
Bogen, Stephane L.; Bennett, Frank; Girijavallabhan,  
Viyyoor M.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 282 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2005085242	A1	20050915	WO 2005-US5924	20050224
---------------	----	----------	----------------	----------

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,  
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,  
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,  
MR, NE, SN, TD, TG

US 2005222047 A1 20051006 US 2005-65647 20050224  
PRIORITY APPLN. INFO.: US 2004-548506P P 20040227

OTHER SOURCE(S): MARPAT 143:306545

TI Preparation of novel peptidyl ketoamides with cyclic p4s as inhibitors of  
NS3 serine protease of hepatitis C virus

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE  
FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 14 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:983762 CAPLUS

DOCUMENT NUMBER: 143:286692

TITLE: Preparation of 3,4-(cyclopentyl)-fused proline  
compounds as inhibitors of hepatitis C virus  
NS3 serine protease

INVENTOR(S):- Njoroge, F. George; Venkatraman, Srikanth; Arasappan,  
Ashok; Velazquez, Francisco; Girijavallabhan, Viyyoor  
M.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 201 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

US 2005197301	A1	20050908	US 2005-64757	20050224
---------------	----	----------	---------------	----------

WO 2005087730	A1	20050922	WO 2005-US5778	20050224
---------------	----	----------	----------------	----------

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,  
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,  
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,  
MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-548655P P 20040227

OTHER SOURCE(S): MARPAT 143:286692

TI Preparation of 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis C virus NS3 serine protease

L23 ANSWER 15 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:739763 CAPLUS

TITLE: Discovery of SCH 503034, a selective, potent HCV NS3 protease inhibitor with oral bioavailability: Potential therapeutic agent for treating hepatitis C viral infection

AUTHOR(S): Njoroge, F. George; Arasappan, A.; Bennett, F.; Bogen, Stephane; Chen, K.; Hendrata, S.; Huang, Y.; Jao, E.; Liu, Y-T.; Lovey, R.; McCormick, J.; Parekh, T.; Pike, R.; Pinto, P.; Pan, W.; Ruan, S.; Santhanam, S.; Vibulbhan, B.; Venkatraman, S.; Wu, W.; Yang, W.; Pichardo, J.; Butkiewicz, N.; Malcolm, B.; Liu, R.; Agrawal, S.; Hart, A.; Kong, S.; Cheng, K-C.; Cui, X.; Hsieh, Y.; Wang, L.; Broske, L.; Prelusky, D.; Korfmacher, W.; White, R.; Bogdanowich-Knipp, S.; Bradley, P.; Prongay, A.; Guo, Z.; Madison, V.; Saksena, A.; Girijavallabhan, V.; Piwinski, J.; Ganguly, A.; Baroudy, B.

CORPORATE SOURCE: Chemical Research, Schering-Plough Research Institute, Kenilworth, NJ, 07033, USA

SOURCE: Abstracts of Papers, 230th ACS National Meeting, Washington, DC, United States, Aug. 28-Sept. 1, 2005 (2005), MEDI-252. American Chemical Society: Washington, D. C.  
CODEN: 69HFCL

DOCUMENT TYPE: Conference; Meeting Abstract; (computer optical disk)

LANGUAGE: English

TI Discovery of SCH 503034, a selective, potent HCV NS3 protease inhibitor with oral bioavailability: Potential therapeutic agent for treating hepatitis C viral infection

L23 ANSWER 16 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:739683 CAPLUS

TITLE: P2 Diamino acid derivatives as hepatitis C virus NS3 serine protease inhibitors

AUTHOR(S): Arasappan, Ashok; Njoroge, F. George; Gu, Haining; Parekh, Tejal N.; Pichardo, John; Butkiewicz, Nancy; Prongay, Andrew; Yao, Nanhua; Girijavallabhan, Viyyoor

CORPORATE SOURCE: Schering Plough Research Institute, Kenilworth, NJ, 07033, USA

SOURCE: Abstracts of Papers, 230th ACS National Meeting, Washington, DC, United States, Aug. 28-Sept. 1, 2005

(2005), MEDI-172. American Chemical Society:  
Washington, D. C.  
CODEN: 69HFCL

DOCUMENT TYPE: Conference; Meeting Abstract; (computer optical disk)  
LANGUAGE: English  
TI P2 Diamino acid derivatives as hepatitis C virus NS3  
serine protease inhibitors

L23 ANSWER 17 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:688587 CAPLUS

DOCUMENT NUMBER: 144:164924

TITLE: Small interfering RNA effectively inhibits protein  
expression and negative strand RNA synthesis from a  
full-length hepatitis C virus clone

AUTHOR(S): Prabhu, Ramesh; Vittal, Padmaja; Yin, Qinyan;  
Flemington, Erik; Garry, Robert; Robichaux, William  
H.; Dash, Srikanta

CORPORATE SOURCE: Department of Pathology and Laboratory Medicine,  
Tulane University Health Sciences Center, New Orleans,  
LA, USA

SOURCE: Journal of Medical Virology (2005), 76(4), 511-519  
CODEN: JMVIDB; ISSN: 0146-6615

PUBLISHER: Wiley-Liss, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Small interfering RNA effectively inhibits protein expression and negative  
strand RNA synthesis from a full-length hepatitis C virus clone

REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 18 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:611991 CAPLUS

DOCUMENT NUMBER: 143:109760

TITLE: Method for treating hepatitis C virus  
infection with non-PEGylated interferon-.alpha. and  
then with PEGylated interferon-.alpha.

INVENTOR(S): Blatt, Lawrence M.

PATENT ASSIGNEE(S): Intermune, Inc., USA

SOURCE: PCT Int. Appl., 117 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005062949	A2	20050714	WO 2004-US43414	20041222
WO 2005062949	A3	20060330		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-532599P P 20031223

TI Method for treating hepatitis C virus infection with non-PEGylated interferon-.alpha. and then with PEGylated interferon-.alpha.

L23 ANSWER 19 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:580501 CAPLUS

DOCUMENT NUMBER: 143:318409

TITLE: T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C

AUTHOR(S): Kaplan, David E.; Sugimoto, Kazushi; Ikeda, Fusao; Stadanlick, Jason; Valiga, Mary; Shetty, Kirti; Reddy, K. Rajender; Chang, Kyong-Mi

CORPORATE SOURCE: Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA

SOURCE: Hepatology (Hoboken, NJ, United States) (2005), 41(6), 1365-1375

CODEN: HPTLD9; ISSN: 0270-9139

PUBLISHER: John Wiley & Sons, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

TI T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 20 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:570872 CAPLUS

DOCUMENT NUMBER: 143:97642

TITLE: Preparation of peptides as inhibitors of  
hepatitis C virus NS3/NS4a serine  
protease

INVENTOR(S): Velazquez, Francisco; Venkatraman, Srikanth; Njoroge,  
F. George

PATENT ASSIGNEE(S): Schering Corporation, USA; Arasappan, Ashok

SOURCE: PCT Int. Appl., 142 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2005058821	A1	20050630	WO 2004-US41579	20041209
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004298498	A1	20050630	AU 2004-298498	20041209
US 2005153900	A1	20050714	US 2004-7910	20041209
PRIORITY APPLN. INFO.: US 2003-528845P P 20031211 WO 2004-US41579 W 20041209				
OTHER SOURCE(S): MARPAT 143:97642				
TI Preparation of peptides as inhibitors of hepatitis C virus NS3/NS4a serine protease				
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS				

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 21 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:523592 CAPLUS

DOCUMENT NUMBER: 143:60255

TITLE: Preparation of prolinamide peptides as  
hepatitis C virus inhibitors

INVENTOR(S): Tu, Yong; Scola, Paul Michael; Good, Andrew Charles;  
Campbell, Jeffrey Allen

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 108 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005054430	A2	20050616	WO 2004-US38967	20041119
WO 2005054430	A3	20050915		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005143316 A1 20050630 US 2004-992566 20041118  
PRIORITY APPLN. INFO.: US 2003-523764P P 20031120

OTHER SOURCE(S): MARPAT 143:60255

TI Preparation of prolinamide peptides as hepatitis C virus inhibitors

L23 ANSWER 22 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:523269 CAPLUS

DOCUMENT NUMBER: 143:38364

TITLE: PPAR agonists for the treatment of hepatitis C virus (HCV) infection

INVENTOR(S): Cortese, Riccardo; Nicosia, Alfredo; Vitelli, Alessandra

PATENT ASSIGNEE(S): Istituto di Ricerche di Biologia Molecolare P Angeletti S.p.A., Italy

SOURCE: PCT Int. Appl., 14 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2005053670 A1 20050616 WO 2004-EP13067 20041117  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,  
SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG

AU 2004294704 A1 20050616 AU 2004-294704 20041117  
PRIORITY APPLN. INFO.: GB 2003-27050 A 20031120  
WO 2004-EP13067 W 20041117

TI PPAR agonists for the treatment of hepatitis C virus  
(HCV) infection

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE  
FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 23 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:490377 CAPLUS

DOCUMENT NUMBER: 143:44074

TITLE: Preparation of depeptidized inhibitors of  
hepatitis C virus NS3 protease

INVENTOR(S): Venkatraman, Srikanth; Girijavallabhan, Viyyoor M.

PATENT ASSIGNEE(S): Schering Corporation, USA; Njoroge, F. George

SOURCE: PCT Int. Appl., 138 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----	----	-----	-----	-----
-------	------	-------	-------	-------

WO 2005051980	A1	20050609	WO 2004-US39131	20041119
---------------	----	----------	-----------------	----------

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,  
SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG

US 2005164921 A1 20050728 US 2004-993394 20041119  
PRIORITY APPLN. INFO.: US 2003-523715P P 20031120  
OTHER SOURCE(S): MARPAT 143:44074

TI Preparation of depeptidized inhibitors of hepatitis C virus  
NS3 protease

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE  
FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 24 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:409553 CAPLUS

DOCUMENT NUMBER: 142:459118

TITLE: HCV NS3-NS4A protease resistance mutants  
affecting the activity of NS3-NS4A  
inhibitory drugs VX-950 and BILN2061 and  
structure-based anti-HCV drug design

INVENTOR(S): Lin, Chao; Lin, Kai

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----	---	-----	-----	-----
-------	-----	-------	-------	-------

WO 2005042570	A1	20050512	WO 2004-US35839	20041027
---------------	----	----------	-----------------	----------

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG

AU 2004285019	A1	20050512	AU 2004-285019	20041027
---------------	----	----------	----------------	----------

US 2005136400	A1	20050623	US 2004-974558	20041027
---------------	----	----------	----------------	----------

EP 1678202	A1	20060712	EP 2004-817468	20041027
------------	----	----------	----------------	----------

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR  
PRIORITY APPLN. INFO.: US 2003-514740P P 20031027

US 2003-525222P P 20031126

US 2004-561662P P 20040413

WO 2004-US35839 W 20041027

TI HCV NS3-NS4A protease resistance mutants affecting the activity  
of NS3-NS4A inhibitory drugs VX-950 and BILN2061 and  
structure-based anti-HCV drug design

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE  
FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 25 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:409350 CAPLUS

DOCUMENT NUMBER: 142:457040

TITLE: Pharmaceutical compositions comprising HCV NS3  
/4A protease inhibitor and cytochrome P 450  
monooxygenase inhibitor for HCV treatment

INVENTOR(S): Tung, Roger D.; Chandorkar, Gurudatt; Perni, Robert B.

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 37 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2005042020	A2	20050512	WO 2004-US35549	20041027
---------------	----	----------	-----------------	----------

WO 2005042020	A3	20050623		
---------------	----	----------	--	--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG

AU 2004285503	A1	20050512	AU 2004-285503	20041027
---------------	----	----------	----------------	----------

CA 2543696	AA	20050512	CA 2004-2543696	20041027
------------	----	----------	-----------------	----------

US 2006003942	A1	20060105	US 2004-974538	20041027
---------------	----	----------	----------------	----------

EP 1677827	A2	20060712	EP 2004-810032	20041027
------------	----	----------	----------------	----------

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR  
PRIORITY APPLN. INFO.: US 2003-514853P P 20031027

WO 2004-US35549 W 20041027

TI Pharmaceutical compositions comprising HCV NS3/4A protease  
inhibitor and cytochrome P 450 monooxygenase inhibitor for HCV  
treatment

L23 ANSWER 26 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:371064 CAPLUS

DOCUMENT NUMBER: 142:430532

TITLE: Preparation of macrocyclic carboxylic acids and  
acylsulfonamides as inhibitors of HCV replication

INVENTOR(S): Blatt, Lawrence M.; Wenglowsky, Steven Mark; Andrews,  
Steven Wade; Jiang, Yutong; Kennedy, April Layne;  
Condroski, Kevin Ronald; Josey, John Anthony; Stengel,  
Peter John; Madduru, Machender R.; Doherty, George  
Andrew; Woodard, Benjamin T.

PATENT ASSIGNEE(S): Intermune, Inc., USA; Array Biopharma Inc.

SOURCE: PCT Int. Appl., 244 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----	----	-----	-----	-----
-------	------	-------	-------	-------

WO 2005037214	A2	20050428	WO 2004-US33970	20041013
---------------	----	----------	-----------------	----------

WO 2005037214	A3	20051103		
---------------	----	----------	--	--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG

AU 2004281780	A1	20050428	AU 2004-281780	20041013
---------------	----	----------	----------------	----------

CA 2540858	AA	20050428	CA 2004-2540858	20041013
------------	----	----------	-----------------	----------

EP 1680137	A2	20060719	EP 2004-795169	20041013
------------	----	----------	----------------	----------

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

US 2005267018 A1 20051201 US 2005-93884 20050329  
NO 2006002089 A 20060509 NO 2006-2089 20060509  
PRIORITY APPLN. INFO.: US 2003-511541P P 20031014  
US 2004-612460P P 20040922  
US 2004-558161P P 20040330  
US 2004-562418P P 20040414  
US 2004-612381P P 20040922  
WO 2004-US33970 W 20041013  
US 2005-64445 A2 20050223  
OTHER SOURCE(S): MARPAT 142:430532  
TI Preparation of macrocyclic carboxylic acids and acylsulfonamides as  
inhibitors of HCV replication

L23 ANSWER 27 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:289077 CAPLUS

DOCUMENT NUMBER: 142:441329

TITLE: Mizoribine inhibits hepatitis C virus RNA  
replication: Effect of combination with  
interferon-.alpha.

AUTHOR(S): Naka, Kazuhito; Ikeda, Masanori; Abe, Ken-ichi;  
Dansako, Hiromichi; Kato, Nobuyuki

CORPORATE SOURCE: Department of Molecular Biology, Okayama University  
Graduate School of Medicine and Dentistry, Okayama,  
700-8558, Japan

SOURCE: Biochemical and Biophysical Research Communications  
(2005), 330(3), 871-879  
CODEN: BBRC A9; ISSN: 0006-291X

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Mizoribine inhibits hepatitis C virus RNA replication: Effect of  
combination with interferon-.alpha.

REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 28 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:281807 CAPLUS

DOCUMENT NUMBER: 142:349026

TITLE: Inhibitors of serine proteases, particularly  
hepatitis C virus NS3-NS4A protease,  
preparation methods, and use in treatment of  
HCV infection

INVENTOR(S): Cottrell, Kevin M.; Perni, Robert P.; Pitlik, Janos;  
Schairer, Wayne C.

PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Incorporated, USA



SOURCE: PCT Int. Appl., 141 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----	---	-----	-----	-----
-------	-----	-------	-------	-------

WO 2005028502	A1	20050331	WO 2004-US30428	20040917
---------------	----	----------	-----------------	----------

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004274468	A1	20050331	AU 2004-274468	20040917
---------------	----	----------	----------------	----------

CA 2538791	AA	20050331	CA 2004-2538791	20040917
------------	----	----------	-----------------	----------

US 2005119189	A1	20050602	US 2004-943265	20040917
---------------	----	----------	----------------	----------

EP 1664091	A1	20060607	EP 2004-784319	20040917
------------	----	----------	----------------	----------

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

PRIORITY APPLN. INFO.: US 2003-504405P P 20030918

WO 2004-US30428 W 20040917

OTHER SOURCE(S): MARPAT 142:349026

TI Inhibitors of serine proteases, particularly hepatitis C virus

NS3-NS4A protease, preparation methods, and use in

treatment of HCV infection

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 29 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:265043 CAPLUS

DOCUMENT NUMBER: 142:441082

TITLE: Allosteric inhibitors of hepatitis C NS5B  
RNA-dependent RNA polymerase

AUTHOR(S): Condon, Stephen M.; LaPorte, Matthew G.; Herbertz, Torsten

CORPORATE SOURCE: Department of Medicinal Chemistry, Gentara Corporation, Malvern, PA, 19355, USA

SOURCE: Current Medicinal Chemistry: Anti-Infective Agents  
(2005), 4(2), 99-110  
CODEN: CMCAFL; ISSN: 1568-0126  
PUBLISHER: Bentham Science Publishers Ltd.  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English  
TI Allosteric inhibitors of hepatitis C NS5B RNA-dependent RNA  
polymerase  
REFERENCE COUNT: 111 THERE ARE 111 CITED REFERENCES  
AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L23 ANSWER 30 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:240970 CAPLUS  
DOCUMENT NUMBER: 142:403245  
TITLE: Anti-viral therapies for hepatitis C virus  
infection: current options and evolving candidate  
drugs  
AUTHOR(S): Fanning, Liam J.  
CORPORATE SOURCE: Hepatitis C Unit, Department of Medicine, Cork  
University Hospital, Cork, Ire.  
SOURCE: Letters in Drug Design & Discovery (2005), 2(2),  
150-161  
CODEN: LDDDAW; ISSN: 1570-1808  
PUBLISHER: Bentham Science Publishers Ltd.  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English  
TI Anti-viral therapies for hepatitis C virus infection: current  
options and evolving candidate drugs  
REFERENCE COUNT: 104 THERE ARE 104 CITED REFERENCES  
AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L23 ANSWER 31 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:219807 CAPLUS  
DOCUMENT NUMBER: 142:298334  
TITLE: Novel peptidomimetic NS3-serine protease  
inhibitors of hepatitis C virus  
INVENTOR(S): Chen, Kevin X.; Njoroge, F. George; Yang, Weiying;  
Vibulbhan, Bancha; Girjavallabhan, Viyyoor M.;  
Venkatraman, Srikanth; Velazquez, Francisco  
PATENT ASSIGNEE(S): Schering Corporation, USA  
SOURCE: PCT Int. Appl., 269 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005021584	A2	20050310	WO 2004-US27422	20040824
WO 2005021584	A3	20050825		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2536570	AA	20050310	CA 2004-2536570	20040824
US 2005085425	A1	20050421	US 2004-925329	20040824
EP 1664090	A2	20060607	EP 2004-782000	20040824
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRIORITY APPLN. INFO.: US 2003-497749P P 20030826				
WO 2004-US27422 W 20040824				
OTHER SOURCE(S): MARPAT 142:298334				
TI Novel peptidomimetic NS3-serine protease inhibitors of hepatitis C virus				

L23 ANSWER 32 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2005:49427 CAPLUS  
DOCUMENT NUMBER: 142:334472

TITLE: Hepatitis C virus-related resistance  
mechanisms to interferon .alpha.-based antiviral  
therapy

AUTHOR(S): Hofmann, Wolf Peter; Zeuzem, Stefan; Sarrazin,  
Christoph

CORPORATE SOURCE: Klinik fuer Innere Medizin II, Universitaetsklinikum  
des Saarlandes, Homburg/Saar, Germany

SOURCE: Journal of Clinical Virology (2005), 32(2), 86-91  
CODEN: JCVIFB; ISSN: 1386-6532

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

TI Hepatitis C virus-related resistance mechanisms to interferon  
.alpha.-based antiviral therapy

REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 33 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1080873 CAPLUS

DOCUMENT NUMBER: 142:56309

TITLE: Preparation of substituted imidazole derivatives as  
antiviral agents

INVENTOR(S): Roberts, Christopher Don; Shi, Dong-Fang; Griffith,  
Ronald Conrad

PATENT ASSIGNEE(S): Genelabs Technologies, Inc., USA

SOURCE: PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----	----	-----	-----	-----
-------	------	-------	-------	-------

WO 2004108687	A2	20041216	WO 2004-US17856	20040604
---------------	----	----------	-----------------	----------

WO 2004108687	A3	20050825		
---------------	----	----------	--	--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG

AU 2004245559	A1	20041216	AU 2004-245559	20040604
---------------	----	----------	----------------	----------

CA 2528044	AA	20041216	CA 2004-2528044	20040604
------------	----	----------	-----------------	----------

US 2005154040	A1	20050714	US 2004-861765	20040604
---------------	----	----------	----------------	----------

EP 1631554	A2	20060308	EP 2004-776308	20040604
------------	----	----------	----------------	----------

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

BR 2004010967	A	20060704	BR 2004-10967	20040604
---------------	---	----------	---------------	----------

CN 1798740	A	20060705	CN 2004-80015278	20040604
------------	---	----------	------------------	----------

NO 2005006100	A	20060301	NO 2005-6100	20051221
---------------	---	----------	--------------	----------

PRIORITY APPLN. INFO.: US 2003-476141P P 20030604

WO 2004-US17856 W 20040604

OTHER SOURCE(S): MARPAT 142:56309

TI Preparation of substituted imidazole derivatives as antiviral agents

L23 ANSWER 34 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1065532 CAPLUS

DOCUMENT NUMBER: 142:169080

TITLE: Combination of a hepatitis C virus  
NS3-NS4A protease inhibitor and alpha  
interferon synergistically inhibits viral RNA  
replication and facilitates viral RNA clearance in  
replicon cells

AUTHOR(S): Lin, Kai; Kwong, Ann D.; Lin, Chao

CORPORATE SOURCE: Vertex Pharmaceuticals Incorporated, Cambridge, MA,  
USA

SOURCE: Antimicrobial Agents and Chemotherapy (2004), 48(12),  
4784-4792

CODEN: AMACCQ; ISSN: 0066-4804

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Combination of a hepatitis C virus NS3-NS4A protease  
inhibitor and alpha interferon synergistically inhibits viral RNA  
replication and facilitates viral RNA clearance in replicon cells

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 35 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1037097 CAPLUS

DOCUMENT NUMBER: 142:38535

TITLE: Preparation of heterocyclic peptides as  
hepatitis C inhibitors

INVENTOR(S): Llinas-Brunet, Montse; Bailey, Murray D.; Bhardwaj,  
Punit; Bordeleau, Josee; Forgione, Pasquale; Ghio,  
Elise; Gorys, Vida; Goudreau, Nathalie; Goulet,  
Sylvie; Halmos, Teddy; Rancourt, Jean

PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany;  
Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.

SOURCE: PCT Int. Appl., 186 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.      KIND    DATE      APPLICATION NO.      DATE

-----  
WO 2004103996      A1    20041202    WO 2004-CA750      20040519

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG

AU 2004240704      A1    20041202    AU 2004-240704      20040519

CA 2522577      AA    20041202    CA 2004-2522577      20040519

EP 1654261      A1    20060510    EP 2004-733750      20040519

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR

BR 2004010456      A    20060606    BR 2004-10456      20040519

CN 1791599      A    20060621    CN 2004-80013783      20040519

US 2005020503      A1    20050127    US 2004-850101      20040520

NO 2005006047      A    20060131    NO 2005-6047      20051219

PRIORITY APPLN. INFO.:      US 2003-472709P    P 20030521

WO 2004-CA750      W 20040519

OTHER SOURCE(S):      MARPAT 142:38535

TI Preparation of heterocyclic peptides as hepatitis C inhibitors

REFERENCE COUNT:      1    THERE ARE 1 CITED REFERENCES AVAILABLE  
FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 36 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:      2004:1027421 CAPLUS

DOCUMENT NUMBER:      142:366789

TITLE:      Lymphocyte T helper-specific reactivity in sustained  
responders to interferon and ribavirin with  
negativation (seroreversion) of anti-hepatitis  
C virus

AUTHOR(S):      Marinho, Rui T.; Pinto, Ruth M.; Santos, Maria L.;  
Carneiro de Moura, Miguel

CORPORATE SOURCE:      Liver Unit, Centre of Gastroenterology, Institute for  
Molecular Medicine, Medical School of Lisbon, Port.

SOURCE:      Liver International (2004), 24(5), 413-418

CODEN: LIINCM; ISSN: 1478-3223

PUBLISHER:      Blackwell Publishing Ltd.

DOCUMENT TYPE:      Journal

LANGUAGE: English  
TI Lymphocyte T helper-specific reactivity in sustained responders to  
interferon and ribavirin with negatvation (seroreversion) of  
anti-hepatitis C virus  
REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES  
AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 37 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2004:997511 CAPLUS  
DOCUMENT NUMBER: 142:85717  
TITLE: Progress and development of small molecule HCV  
antivirals  
AUTHOR(S): Ni, Zhi-Jie; Wagman, Allan S.  
CORPORATE SOURCE: Chiron Corporation, Emeryville, CA, 94608, USA  
SOURCE: Current Opinion in Drug Discovery & Development  
(2004), 7(4), 446-459  
CODEN: CODDF; ISSN: 1367-6733  
PUBLISHER: Thomson Scientific  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English  
TI Progress and development of small molecule HCV antivirals  
REFERENCE COUNT: 101 THERE ARE 101 CITED REFERENCES  
AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L23 ANSWER 38 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2004:927230 CAPLUS  
DOCUMENT NUMBER: 141:395807  
TITLE: Preparation of macrocyclic isoquinoline peptide  
inhibitors of hepatitis C virus  
INVENTOR(S): McPhee, Fiona; Campbell, Jeffrey Allen; Li, Wenying;  
D'Andrea, Stanley; Zheng, Zhizhen Barbara; Good,  
Andrew Charles; Carini, David J.; Johnson, Barry L.;  
Scola, Paul Michael  
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
SOURCE: PCT Int. Appl., 280 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----

WO 2004094452 A2 20041104 WO 2004-US11824 20040416  
WO 2004094452 A3 20050519

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,  
TD, TG

US 2005090432 A1 20050428 US 2004-825693 20040416  
EP 1629000 A2 20060301 EP 2004-759941 20040416

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

NO 2005004841 A 20060111 NO 2005-4841 20051019

PRIORITY APPLN. INFO.: US 2003-463423P P 20030416  
WO 2004-US11824 W 20040416

OTHER SOURCE(S): MARPAT 141:395807

TI Preparation of macrocyclic isoquinoline peptide inhibitors of  
hepatitis C virus

L23 ANSWER 39 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:633913 CAPLUS

DOCUMENT NUMBER: 141:174074

TITLE: Preparation of indole-6-carboxylic acids and related  
compounds as hepatitis C viral polymerase  
inhibitors

INVENTOR(S): Beaulieu, Pierre Louis; Brochu, Christian; Chabot,  
Chatherine; Jolicoeur, Eric; Kawai, Stephen; Poupart,  
Marc-Andre; Tsantrizos, Youla S.

PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany;  
Boehringer Ingelheim Pharma GmbH & Co Kg

SOURCE: PCT Int. Appl., 323 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004065367	A1	20040805	WO 2004-CA18	20040119
WO 2004065367	C1	20060713		



W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 US 2004171626 A1 20040902 US 2004-755256 20040112  
 AU 2004205429 A1 20040805 AU 2004-205429 20040119  
 CA 2511307 AA 20040805 CA 2004-2511307 20040119  
 EP 1587787 A1 20051026 EP 2004-703130 20040119  
 R: AT, BE, CH, DE, DK, ES, GB, LI, LU, SE, PT, LT, LV, FI, RO, MK, AL, TR, BG, CZ, EE, HU, SK  
 BR 2004006926 A 20060103 BR 2004-6926 20040119  
 CN 1764641 A 20060426 CN 2004-80007831 20040119  
 JP 2006517536 T2 20060727 JP 2006-500429 20040119  
 NO 2005003892 A 20051005 NO 2005-3892 20050819  
 PRIORITY APPLN. INFO.: US 2003-441871P P 20030122  
 WO 2004-CA18 W 20040119  
 OTHER SOURCE(S): MARPAT 141:174074  
 TI Preparation of indole-6-carboxylic acids and related compounds as hepatitis C viral polymerase inhibitors  
 REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 40 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2004:618635 CAPLUS  
 DOCUMENT NUMBER: 141:364968  
 TITLE: Expression of hepatitis C virus core protein inhibits interferon-induced nuclear import of STATs  
 AUTHOR(S): Melen, Krister; Fagerlund, Riku; Nyqvist, Maria; Keskinen, Paivi; Julkunen, Ilkka  
 CORPORATE SOURCE: Laboratory of Infectious Disease Immunology, Department of Microbiology, National Public Health Institute, Helsinki, Finland  
 SOURCE: Journal of Medical Virology (2004), 73(4), 536-547  
 CODEN: JMVIDB; ISSN: 0146-6615  
 PUBLISHER: Wiley-Liss, Inc.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 TI Expression of hepatitis C virus core protein inhibits interferon-induced nuclear import of STATs

REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 41 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:565414 CAPLUS

DOCUMENT NUMBER: 141:172561

TITLE: Sequential changes of hepatitis C virus  
antibody profiles during treatment of  
chronic hepatitis C of genotype 1b:  
Pretreatment antibody response to E2/NS1 correlated  
sustained response

AUTHOR(S): Chu, C. M.; Sheen, I. S.; Liaw, Y. F.

CORPORATE SOURCE: Liver Research Unit, Chang Gung Memorial Hospital,  
Taipei, 105, Taiwan

SOURCE: Infection (Munich, Germany) (2004), 32(3), 153-156

CODEN: IFTNAL; ISSN: 0300-8126

PUBLISHER: Urban & Vogel Medien und Medizin Verlagsgesellschaft  
mbH

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Sequential changes of hepatitis C virus antibody profiles during  
treatment of chronic hepatitis C of genotype 1b:

Pretreatment antibody response to E2/NS1 correlated sustained response

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 42 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:331761 CAPLUS

DOCUMENT NUMBER: 140:357668

TITLE: Preparation of tripeptides as hepatitis C  
virus inhibitors

INVENTOR(S): Campbell, Jeffrey Allen; D'Andrea, Stanley; Good,  
Andrew; Li, Jianqing; McPhee, Fiona; Ripka, Amy;  
Scola, Paul Michael; Tu, Yong

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: U.S. Pat. Appl. Publ., 139 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----

US 2004077551 A1 20040422 US 2003-441428 20030520  
 US 6878722 B2 20050412  
 WO 2004043339 A2 20040527 WO 2003-US15780 20030520  
 WO 2004043339 A3 20040722  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,  
 PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,  
 TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 AU 2003301959 A1 20040603 AU 2003-301959 20030520  
 EP 1505945 A2 20050216 EP 2003-808384 20030520  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 JP 2006501307 T2 20060112 JP 2004-551405 20030520  
 NO 2004004895 A 20041228 NO 2004-4895 20041110  
 PRIORITY APPLN. INFO.: US 2002-382149P P 20020520  
 WO 2003-US15780 W 20030520  
 OTHER SOURCE(S): MARPAT 140:357668  
 TI Preparation of tripeptides as hepatitis C virus inhibitors  
 REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES  
 AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 43 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2004:203541 CAPLUS  
 DOCUMENT NUMBER: 140:253912  
 TITLE: Preparation of hydroxyprolinamide peptides as  
 hepatitis C virus inhibitors  
 INVENTOR(S): Ripka, Amy; Campbell, Jeffrey Allen; Good, Andrew  
 Charles; Scola, Paul Michael; Sin, Ny; Venables, Brian  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: U.S. Pat. Appl. Publ., 82 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004048802	A1	20040311	US 2003-441827	20030520

US 7041698 B2 20060509  
WO 2004032827 A2 20040422 WO 2003-US15856 20030520  
WO 2004032827 A3 20041014

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,  
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003299519 A1 20040504 AU 2003-299519 20030520

EP 1506172 A2 20050216 EP 2003-799806 20030520

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2006507264 T2 20060302 JP 2004-543197 20030520

NO 2004004897 A 20050218 NO 2004-4897 20041110

PRIORITY APPLN. INFO.: US 2002-382156P P 20020520

WO 2003-US15856 W 20030520

OTHER SOURCE(S): MARPAT 140:253912

TI Preparation of hydroxyprolinamide peptides as hepatitis C virus  
inhibitors

L23 ANSWER 44 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:80452 CAPLUS

DOCUMENT NUMBER: 140:122759

TITLE: Thionucleoside derivatives as inhibitors of  
RNA-dependent RNA viral polymerase

INVENTOR(S): Olsen, David B.; Bhat, Balkrishen; Cook, Phillip Dan

PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Isis Pharmaceuticals, Inc.

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009020	A2	20040129	WO 2003-US22556	20030718
WO 2004009020	A3	20050224		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,				

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG,  
 PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,  
 TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 AU 2003256619 A1 20040209 AU 2003-256619 20030718  
 US 2006122154 A1 20060608 US 2005-520925 20050926  
 PRIORITY APPLN. INFO.: US 2002-398237P P 20020724  
 WO 2003-US22556 W 20030718  
 OTHER SOURCE(S): MARPAT 140:122759  
 TI Thionucleoside derivatives as inhibitors of RNA-dependent RNA viral  
 polymerase

L23 ANSWER 45 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2004:20801 CAPLUS  
 DOCUMENT NUMBER: 140:70987  
 TITLE: Nucleoside derivatives as inhibitors of RNA-dependent  
 RNA viral polymerase  
 INVENTOR(S): Olsen, David B.; Maccoss, Malcolm; Bhat, Balkrishen;  
 Eldrup, Anne B.  
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Isis Pharmaceuticals, Inc.  
 SOURCE: PCT Int. Appl., 42 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004003138	A2	20040108	WO 2003-US19776	20030623
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG CA 2488484 AA 20040108 CA 2003-2488484 20030623 AU 2003269892 A1 20040119 AU 2003-269892 20030623 EP 1572945 A2 20050914 EP 2003-751779 20030623				

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 JP 2006512288 T2 20060413 JP 2004-517749 20030623  
 PRIORITY APPLN. INFO.: US 2002-392438P P 20020627  
 WO 2003-US19776 W 20030623  
 OTHER SOURCE(S): MARPAT 140:70987  
 TI Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase

L23 ANSWER 46 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:20697 CAPLUS

DOCUMENT NUMBER: 140:87662

TITLE: 2'- and 3'-nucleoside prodrugs for treating  
 Flaviviridae infections

INVENTOR(S): Sommadossi, Jean-pierre; La Colla, Paolo; Storer,  
 Richard; Gosselin, Gilles

PATENT ASSIGNEE(S): Idenix (Cayman) Limited, Cayman I.; Centre National de  
 la Recherche Scientifique; Universita Degli Studi di  
 Cagliari

SOURCE: PCT Int. Appl., 2498 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004003000	A2	20040108	WO 2003-IB3901	20030627
WO 2004003000	A3	20041104		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,				
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,				
TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2490200	AA	20040108	CA 2003-2490200	20030627
AU 2003263412	A1	20040119	AU 2003-263412	20030627
EP 1525209	A2	20050427	EP 2003-761749	20030627
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1678621	A	20051005	CN 2003-820690	20030627
JP 2005537242	T2	20051208	JP 2004-517162	20030627

CN 1761677 A 20060419 CN 2003-820501 20030627  
WO 2005020884 A2 20050310 WO 2004-US15395 20040514  
WO 2005020884 A3 20060622

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG

EP 1656093 A2 20060517 EP 2004-776022 20040514

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

NO 2005000466 A 20050323 NO 2005-466 20050127

PRIORITY APPLN. INFO.: US 2002-392350P P 20020628

US 2002-392351P P 20020628

US 2003-466194P P 20030428

US 2003-470949P P 20030514

WO 2003-IB3901 W 20030627

WO 2004-US15395 W 20040514

OTHER SOURCE(S): MARPAT 140:87662

TI 2'- and 3'-nucleoside prodrugs for treating Flaviviridae infections

L23 ANSWER 47 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:20443 CAPLUS

DOCUMENT NUMBER: 140:70984

TITLE: 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine  
for treatment of flaviviridae infections

INVENTOR(S): Sommadossi, Jean-Pierre; La Colla, Paolo

PATENT ASSIGNEE(S): Idenix (Cayman) Limited, Cayman I.; Universita Degli  
Studi di Cagliari

SOURCE: PCT Int. Appl., 110 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004002422	A2	20040108	WO 2003-US20431	20030627
WO 2004002422	A3	20050407		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG,  
 PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,  
 TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 CA 2489552 AA 20040108 CA 2003-2489552 20030627  
 AU 2003248748 A1 20040119 AU 2003-248748 20030627  
 US 2004077587 A1 20040422 US 2003-607909 20030627  
 EP 1536804 A2 20050608 EP 2003-762183 20030627  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 CN 1678326 A 20051005 CN 2003-820701 20030627  
 JP 2005533824 T2 20051110 JP 2004-518041 20030627  
 WO 2005020884 A2 20050310 WO 2004-US15395 20040514  
 WO 2005020884 A3 20060622  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG  
 EP 1656093 A2 20060517 EP 2004-776022 20040514  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR  
 NO 2005000490 A 20050127 NO 2005-490 20050127  
 PRIORITY APPLN. INFO.: US 2002-392351P P 20020628  
 US 2003-466194P P 20030428  
 US 2003-470949P P 20030514  
 WO 2003-US20431 W 20030627  
 WO 2004-US15395 W 20040514  
 OTHER SOURCE(S): MARPAT 140:70984  
 TI 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for  
 treatment of flaviviridae infections

L23 ANSWER 48 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2003:1006709 CAPLUS



DOCUMENT NUMBER: 140:35898  
 TITLE: Carbocyclic nucleoside derivatives as inhibitors of  
 RNA-dependent RNA viral polymerase  
 INVENTOR(S): Bhat, Balkrishen; Bhat, Neelima; Dande, Prasad;  
 Eldrup, Anne B.; Olsen, David B.; MacCoss, Malcolm  
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Isis Pharmaceuticals, Inc.  
 SOURCE: PCT Int. Appl., 74 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 46  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003105770	A2	20031224	WO 2003-US18841	20030614
WO 2003105770	A3	20041007		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2488842	AA	20031224	CA 2003-2488842	20030614
AU 2003251524	A1	20031231	AU 2003-251524	20030614
EP 1515971	A2	20050323	EP 2003-760371	20030614
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005533777	T2	20051110	JP 2004-512678	20030614
PRIORITY APPLN. INFO.: US 2002-389161P P 20020617				
WO 2003-US18841 W 20030614				
OTHER SOURCE(S): MARPAT 140:35898				
TI Carbocyclic nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase				

L23 ANSWER 49 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2003:975370 CAPLUS  
 DOCUMENT NUMBER: 140:22510  
 TITLE: Current therapy and new molecular approaches to  
 antiviral treatment and prevention of  
 hepatitis C  
 AUTHOR(S): Huegle, Thomas; Cerny, Andreas

CORPORATE SOURCE: Clinica Medica, Ospedale Civico, Lugano, CH-6903,  
Switz.  
SOURCE: Reviews in Medical Virology (2003), 13(6), 361-371  
CODEN: RMVIEW; ISSN: 1052-9276  
PUBLISHER: John Wiley & Sons Ltd.  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English  
TI Current therapy and new molecular approaches to antiviral  
treatment and prevention of hepatitis C  
REFERENCE COUNT: 79 THERE ARE 79 CITED REFERENCES  
AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT.

L23 ANSWER 50 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:950866 CAPLUS

DOCUMENT NUMBER: 140:16976

TITLE: Preparation of peptide heterocyclic sulfonamide  
derivatives as hepatitis C virus inhibitors

INVENTOR(S): Campbell, Jeffrey Allen; Good, Andrew Charles

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 112 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003099316	A1	20031204	WO 2003-US15786	20030520
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003248535	A1	20031212	AU 2003-248535	20030520
US 2004072761	A1	20040415	US 2003-441830	20030520
US 6869964	B2	20050322		
EP 1506000	A1	20050216	EP 2003-755389	20030520
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

JP 2005526144 T2 20050902 JP 2004-506840 20030520  
NO 2004004808 A 20041217 NO 2004-4808 20041104  
PRIORITY APPLN. INFO.: US 2002-382104P P 20020520  
WO 2003-US15786 W 20030520  
OTHER SOURCE(S): MARPAT 140:16976  
TI Preparation of peptide heterocyclic sulfonamide derivatives as  
hepatitis C virus inhibitors  
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE  
FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE'RE FORMAT

L23 ANSWER 51 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:950834 CAPLUS

DOCUMENT NUMBER: 140:16975

TITLE: Preparation of peptides as hepatitis C virus  
inhibitors

INVENTOR(S): Wang, Xiangdong Alan; Sun, Li-Quang; Sit, Sing-Yuen;  
Sin, Ny; Scola, Paul Michael; Hewawasam, Piyasena;  
Good, Andrew Charles; Chen, Yan; Campbell, Jeffrey  
Allen

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 675 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003099274	A1	20031204	WO 2003-US15755	20030520
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2486308	AA	20031204	CA 2003-2486308	20030520
AU 2003241510	A1	20031212	AU 2003-241510	20030520
US 2004106559	A1	20040603	US 2003-441657	20030520
US 6995174	B2	20060207		
EP 1505963	A1	20050216	EP 2003-731248	20030520

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 BR 2003011132 A 20050308 BR 2003-11132 20030520  
 CN 1668297 A 20050914 CN 2003-817068 20030520  
 JP 2005533028 T2 20051104 JP 2004-506798 20030520  
 NO 2004004807 A 20041216 NO 2004-4807 20041104  
 PRIORITY APPLN. INFO.: US 2002-382055P P 20020520  
 WO 2003-US15755 W 20030520  
 OTHER SOURCE(S): MARPAT 140:16975  
 TI Preparation of peptides as hepatitis C virus inhibitors  
 REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE  
 FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 52 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:874780 CAPLUS

DOCUMENT NUMBER: 139:363583

TITLE: Non-structural ns3/4a fusion gene from  
 hepatitis C virus optimized for codons most  
 frequently used in humans, and uses in immunogenic  
 preparations

INVENTOR(S): Sallberg, Matti

PATENT ASSIGNEE(S): Tripep AB, Swed.

SOURCE: U.S. Pat. Appl. Publ., 83 pp., Cont.-in-part of U.S.  
 Ser. No. 930,591.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003206919	A1	20031106	US 2002-307047	20021126
US 7022830	B2	20060404		
US 2002136740	A1	20020926	US 2001-929955	20010815
US 6858590	B2	20050222		
US 2004092730	A1	20040513	US 2001-930591	20010815
US 6960569	B2	20051101		
CA 2506820	AA	20040610	CA 2003-2506820	20031125
WO 2004048402	A2	20040610	WO 2003-IB6361	20031125
WO 2004048402	A3	20040729		
WO 2004048402	B1	20041007		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,  
 NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,  
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,  
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 AU 2003290385      A1    20040618    AU 2003-290385      20031125  
 EP 1567190      A2    20050831    EP 2003-782748      20031125  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, BG, CZ, EE, HU, SK  
 CN 1741817      A    20060301    CN 2003-80109208      20031125  
 US 2005124573      A1    20050609    US 2005-43808      20050125  
 US 2006062801      A1    20060323    US 2005-249893      20051013  
 PRIORITY APPLN. INFO.:      US 2000-225767P    P 20000817  
    US 2000-229175P    P 20000829  
    US 2001-929955    A2 20010815  
    US 2001-930591    A2 20010815  
    US 2002-307047    A 20021126  
    WO 2003-~~IB~~6361    W 20031125  
 TI    Non-structural ns3/4a fusion gene from hepatitis C  
       virus optimized for codons most frequently used in humans, and uses in  
       immunogenic preparations

L23 ANSWER 53 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:      2003:644155 CAPLUS

DOCUMENT NUMBER:      140:174468

TITLE:                    Antiviral treatment of recurrent  
                               hepatitis C virus (HCV) infection after liver  
                               transplantation: association of a strong,  
                               multispecific, and long-lasting CD4+ T cell response  
                               with HCV-elimination

AUTHOR(S):              Schirren, Carl Albrecht; Zachoval, Reinhart; Gerlach,  
                               Joern Tilman; Ulsenheimer, Axel; Gruener, Norbert  
                               Hubert; Diepolder, Helmut Michael; Baretton, Gustavo;  
                               Schraut, Winfried; Rau, Horst-Guenter; Nitschko, Hans;  
                               Pape, Gerd Rudolf; Jung, Maria-Christina

CORPORATE SOURCE:      Klinikum Grosshadern, Department of Medicine II,  
                               University of Munich, Munich, D-81377, Germany

SOURCE:                    Journal of Hepatology (2003), 39(3), 397-404  
                               CODEN: JOHEEC; ISSN: 0168-8278

PUBLISHER:                Elsevier Science B.V.

DOCUMENT TYPE:          Journal

LANGUAGE:                English

TI    Antiviral treatment of recurrent hepatitis C virus  
       (HCV) infection after liver transplantation: association of a strong,

multispecific, and long-lasting CD4+ T cell response with HCV-elimination  
REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 54 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:524481 CAPLUS

DOCUMENT NUMBER: 139:148323

TITLE: The role of specific CD4+ T helper cell response in  
the course of hepatitis C virus infection

AUTHOR(S): Barbakadze, G.; Kamkamidze, G.; Butsashvili, M.;  
Kiladze, M.; Jatchvliani, D.

CORPORATE SOURCE: Thoracoabdominal Clinic, State Med. Acad., Tbilisi,  
Georgia

SOURCE: Sbornik Lekarsky (2003), 104(1), 79-83

CODEN: SBLEA2; ISSN: 0036-5327

PUBLISHER: Karolinum - Nakladatelstvi Univerzity Karlovy

DOCUMENT TYPE: Journal

LANGUAGE: English

TI The role of specific CD4+ T helper cell response in the course of  
hepatitis C virus infection

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES

AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 55 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:383765 CAPLUS

DOCUMENT NUMBER: 139:190428

TITLE: Current antiviral therapy for chronic  
hepatitis C including liver transplantation  
and hepatic resection

AUTHOR(S): Hanazaki, Kazuhiro

CORPORATE SOURCE: Division of Gastroenterological Surgery, Department of  
Surgery, Shinshu University School of Medicine,  
Matsumoto, 390-8621, Japan

SOURCE: Current Medicinal Chemistry: Anti-Infective Agents  
(2003), 2(2), 103-111

CODEN: CMCAFL; ISSN: 1568-0126

PUBLISHER: Bentham Science Publishers Ltd.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

TI Current antiviral therapy for chronic hepatitis C including  
liver transplantation and hepatic resection

REFERENCE COUNT: 65 THERE ARE 65 CITED REFERENCES

AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 56 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2003:155830 CAPLUS  
 DOCUMENT NUMBER: 138:350603  
 TITLE: Interference of hepatitis C virus RNA  
 replication by short interfering RNAs  
 AUTHOR(S): Kapadia, Sharookh B.; Brideau-Andersen, Amy; Chisari,  
 Francis V.  
 CORPORATE SOURCE: Department of Molecular and Experimental Medicine, The  
 Scripps Research Institute, La Jolla, CA, 92037, USA  
 SOURCE: Proceedings of the National Academy of Sciences of the  
 United States of America (2003), 100(4), 2014-2018  
 CODEN: PNASA6; ISSN: 0027-8424  
 PUBLISHER: National Academy of Sciences  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 TI Interference of hepatitis C virus RNA replication by short  
 interfering RNAs  
 REFERENCE COUNT: 65 THERE ARE 65 CITED REFERENCES  
 AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 57 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2003:98035 CAPLUS  
 DOCUMENT NUMBER: 138:131080  
 TITLE: Compositions and methods for determining  
 susceptibility of hepatitis C virus to  
 antiviral drugs  
 INVENTOR(S): Parkin, Neil T.; Gamarnik, Andrea  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U.S.  
 Ser. No. 126,559.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003028011	A1	20030206	US 2002-139069	20020503
US 2002034732	A1	20020321	US 1998-126559	19980730
WO 2003093492	A2	20031113	WO 2003-US13791	20030505
WO 2003093492	A3	20040401		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,  
UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003265959 A1 20031117 AU 2003-265959 20030505

PRIORITY APPLN. INFO.: US 1997-54257P P 19970730

US 1998-126559 A2 19980730

US 2002-139069 A 20020503

WO 2003-US13791 W 20030505

TI Compositions and methods for determining susceptibility of  
hepatitis C virus to antiviral drugs

L23 ANSWER 58 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:97396 CAPLUS

DOCUMENT NUMBER: 138:153435

TITLE: Preparation of indole-6-carboxylic acids and related  
compounds as hepatitis C viral polymerase  
inhibitors

INVENTOR(S): Beaulieu, Pierre Louis; Fazal, Gulrez; Kukolj, George;  
Jolicoeur, Eric; Gillard, James; Poupart, Marc-Andre;  
Rancourt, Jean

PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Can.

SOURCE: PCT Int. Appl., 112 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2003010140	A2	20030206	WO 2002-CA1127	20020718
---------------	----	----------	----------------	----------

WO 2003010140	A3	20030710		
---------------	----	----------	--	--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,  
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,



CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 CA 2450033 AA 20030206 CA 2002-2450033 20020718  
 US 2003176433 A1 20030918 US 2002-198680 20020718  
 US 2004024190 A1 20040205 US 2002-198384 20020718  
 EP 1414441 A2 20040506 EP 2002-750715 20020718  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK  
 BR 2002011477 A 20040817 BR 2002-11477 20020718  
 CN 1558759 A 20041229 CN 2002-818790 20020718  
 JP 2005504030 T2 20050210 JP 2003-515499 20020718  
 CN 1610546 A 20050427 CN 2002-818797 20020718  
 ZA 2004000122 A 20041103 ZA 2004-122 20040108  
 ZA 2004000240 A 20041101 ZA 2004-240 20040113  
 US 2006160798 A1 20060720 US 2006-333163 20060117  
 PRIORITY APPLN. INFO.: US 2001-307674P P 20010725  
 US 2001-338061P P 20011207  
 US 2002-198384 A3 20020718  
 WO 2002-CA1127 W 20020718  
 OTHER SOURCE(S): MARPAT 138:153435  
 TI Preparation of ~~indole-6~~-carboxylic acids and related compounds as  
 hepatitis C viral polymerase inhibitors

L23 ANSWER 59 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:23927 CAPLUS

DOCUMENT NUMBER: 138:105435

TITLE: Antiviral effect and virus-host interactions in  
 response to alpha interferon, gamma interferon,  
 poly(I)-poly(C), tumor necrosis factor alpha, and  
 ribavirin in hepatitis C virus  
 subgenomic replicons

AUTHOR(S): Lanford, Robert E.; Guerra, Bernadette; Lee, Helen;  
 Averett, Devron R.; Pfeiffer, Brad; Chavez, Deborah;  
 Notvall, Lena; Bigger, Catherine

CORPORATE SOURCE: Department of Virology and Immunology, Southwest  
 National Primate Research Center, Southwest Foundation  
 for Biomedical Research, San Antonio, TX, 78227, USA

SOURCE: Journal of Virology (2003), 77(2), 1092-1104  
 CODEN: JOVIAM; ISSN: 0022-538X

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Antiviral effect and virus-host interactions in response to alpha  
 interferon, gamma interferon, poly(I)-poly(C), tumor necrosis factor  
 alpha, and ribavirin in hepatitis C virus subgenomic  
 replicons

REFERENCE COUNT: 68 THERE ARE 68 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 60 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:682658 CAPLUS

DOCUMENT NUMBER: 138:23465

TITLE: CD4 T lymphocyte proliferative responses to  
hepatitis C virus (HCV) antigens in patients  
coinfected with HCV and human immunodeficiency virus  
who responded to anti-HCV treatment

AUTHOR(S): Legrand, Elisabeth; Neau, Didier; Galperine, Tatiana;  
Trimoulet, Pascale; Moreau, Jean-Francois; Pitard,  
Vincent; Lacut, Jean-Yves; Ragnaud, Jean-Marie; Dupon,  
Michel; Le Bail, Brigitte; Bernard, Noelle; Schvoerer,  
Evelyne; Houghton, Michael; Fleury, Herve; Lafon,  
Marie-Edith

CORPORATE SOURCE: Virology Laboratory, Bordeaux 2 University, Fr.

SOURCE: Journal of Infectious Diseases (2002), 186(3), 302-311

CODEN: JIDIAQ; ISSN: 0022-1899

PUBLISHER: University of Chicago Press

DOCUMENT TYPE: Journal

LANGUAGE: English

TI CD4 T lymphocyte proliferative responses to hepatitis C virus  
(HCV) antigens in patients coinfectd with HCV and human immunodeficiency  
virus who responded to anti-HCV treatment

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 61 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:555511 CAPLUS

DOCUMENT NUMBER: 137:109450

TITLE: Preparation of nucleoside derivatives as inhibitors of  
RNA-dependent RNA viral polymerase

INVENTOR(S): Carroll, Steven S.; Maccoss, Malcolm; Olsen, David B.;  
Bhat, Balkrishen; Bhat, Neelima; Cook, Phillip Dan;  
Eldrup, Anne B.; Prakash, Thazha P.; Prhavc, Marija;  
Song, Quanlai

PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Isis Pharmaceuticals, Inc.

SOURCE: PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002057287	A2	20020725	WO 2002-US3086	20020118
WO 2002057287	A3	20021010		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2434386	AA	20020825	CA 2002-2434386	20020118
US 2002147160	A1	20021010	US 2002-52318	20020118
US 6777395	B2	20040817		
EE 200300338	A	20031015	EE 2003-338	20020118
EP 1355916	A2	20031029	EP 2002-709299	20020118
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002006614	A	20040217	BR 2002-6614	20020118
CN 1498221	A	20040519	CN 2002-806977	20020118
JP 2004520367	T2	20040708	JP 2002-557963	20020118
NZ 526703	A	20041224	NZ 2002-526703	20020118
US 2004072788	A1	20040415	US 2003-431657	20030507
ZA 2003005078	A	20040521	ZA 2003-5078	20030630
BG 108000	A	20040831	BG 2003-108000	20030717
NO 2003003289	A	20030919	NO 2003-3289	20030721
US 2004067901	A1	20040408	US 2003-688691	20031017
US 2005272676	A1	20051208	US 2005-200499	20050809
PRIORITY APPLN. INFO.:			US 2001-263313P	P 20010122
			US 2001-282069P	P 20010406
			US 2001-299320P	P 20010619
			US 2001-344528P	P 20011025
			US 2002-52318	A3 20020118
			WO 2002-US3086	W 20020118
			US 2003-431657	B1 20030507
OTHER SOURCE(S):		MARPAT 137:109450		
TI Preparation of nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase				

L23 ANSWER 62 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2002:171885 CAPLUS  
 DOCUMENT NUMBER: 136:232547  
 TITLE: Preparation of peptidomimetic protease inhibitors

INVENTOR(S): Babine, Robert Edward; Chen, Shu Hui; Lamar, Jason  
Eric; Snyder, Nancy June; Sun, Xicheng David; Tebbe,  
Mark Joseph; Victor, Frantz; Wang, Q. May; Yip, Yvonne  
Yee Mai; Collado, Ivan; Garcia-Paredes, Cristina;  
Parker, Raymond Samuel, III; Jin, Ling; Guo, Deqi;  
Glass, John Irvin

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 424 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018369	A2	20020307	WO 2001-US26008	20010831
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2419607	AA	20020307	CA 2001-2419607	20010831
AU 2001088318	A5	20020313	AU 2001-88318	20010831
EP 1320540	A2	20030625	EP 2001-968040	20010831
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004517047	T2	20040610	JP 2002-523884	20010831
BR 2001013666	A	20050927	BR 2001-13666	20010831
NO 2003000928	A	20030416	NO 2003-928	20030227
ZA 2003001641	A	20040621	ZA 2003-1641	20030227
US 2005197299	A1	20050908	US 2004-344112	20041217
PRIORITY APPLN. INFO.: US 2000-229398P P 20000831				
US 2001-277641P P 20010321				
WO 2001-US26008 W 20010831				
OTHER SOURCE(S): MARPAT 136:232547				
TI Preparation of peptidomimetic protease inhibitors				

L23 ANSWER 63 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:142750 CAPLUS

DOCUMENT NUMBER: 136:196947

TITLE: A naturally occurring fusion protein of non-structural  
proteins NS3/4a of hepatitis C  
virus for use as an antigen in vaccines

INVENTOR(S): Sallberg, Matti

PATENT ASSIGNEE(S): Triep AB, Swed.

SOURCE: PCT Int. Appl., 90 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2002014362	A2	20020221	WO 2001-IB1774	20010815
---------------	----	----------	----------------	----------

WO 2002014362	A3	20031113		
---------------	----	----------	--	--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,  
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,  
VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,  
KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,  
IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG

AU 2001090178	A5	20020225	AU 2001-90178	20010815
---------------	----	----------	---------------	----------

PRIORITY APPLN. INFO.: US 2000-225767P P 20000817

US 2000-229175P P 20000829

US 2000-705547 A 20001103

WO 2001-IB1774 W 20010815

TI A naturally occurring fusion protein of non-structural proteins  
NS3/4a of hepatitis C virus for use as an antigen in  
vaccines

L23 ANSWER 64 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:90018 CAPLUS

DOCUMENT NUMBER: 136:135031

TITLE: Preparation of novel imidazolidinones as NS3  
-serine protease inhibitors of hepatitis C  
virus

INVENTOR(S): Arasappan, Ashok; Parekh, Tejal; Njoroge, F. George;  
Girijavallabhan, Viyyoor Moopil; Ganguily, Ashit K.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 88 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008198	A2	20020131	WO 2001-US22828	20010719
WO 2002008198	A3	20020718		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2410766	AA	20020131	CA 2001-2410766	20010719
US 2002102235	A1	20020801	US 2001-909077	20010719
US 6838475	B2	20050104		
EP 1301486	A2	20030416	EP 2001-961676	20010719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004515464	T2	20040527	JP 2002-514104	20010719
PRIORITY APPLN. INFO.: US 2000-220110P P 20000721				
WO 2001-US22828 W 20010719				
OTHER SOURCE(S): MARPAT 136:135031				
TI Preparation of novel imidazolidinones as NS3-serine protease inhibitors of hepatitis C virus				

L23 ANSWER 65 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2002:90007 CAPLUS  
DOCUMENT NUMBER: 136:151439

TITLE: Preparation of novel peptides as NS3-serine protease inhibitors of hepatitis C virus

INVENTOR(S): Saksena, Anil K.; Girjavallabhan, Viyyoor Moopil; Bogen, Stephane L.; Lovey, Raymond G.; Jao, Edwin E.; Bennett, Frank; McCormick, Jinping L.; Wang, Haiyan; Pike, Russell E.; Liu, Yi-Tsung; Chan, Tin-Yau; Zhu, Zhaoning; Arasappan, Ashok; Chen, Kevin X.; Venkatraman, Srikanth; Parekh, Tejal N.; Pinto, Patrick A.; Santhanam, Bama; Njoroge, F. George; Ganguly, Ashit K.; Vaccaro, Henry A.; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita; Tamura, Susan Y.

PATENT ASSIGNEE(S): Schering Corporation, USA; Corvas International, Inc.

SOURCE: PCT Int. Appl., 188 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008187	A1	20020131	WO 2001-US22813	20010719
WO 2002008187	C2	20030103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2410682	AA	20020131	CA 2001-2410682	20010719
US 2002160962	A1	20021031	US 2001-909012	20010719
EP 1303487	A1	20030423	EP 2001-959041	20010719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012666	A	20030610	BR 2001-12666	20010719
JP 2004513881	T2	20040513	JP 2002-514094	20010719
NZ 523781	A	20041029	NZ 2001-523781	20010719
ZA 2002010311	A	20040319	ZA 2002-10311	20021219
NO 2003000271	A	20030318	NO 2003-271	20030120
US 2005176648	A1	20050811	US 2005-89192	20050324
PRIORITY APPLN. INFO.: US 2000-220107P P 20000721				
US 2001-909012 A3 20010719				
WO 2001-US22813 W 20010719				
OTHER SOURCE(S): MARPAT 136:151439				
TI Preparation of novel peptides as NS3-serine protease inhibitors of hepatitis C virus				
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS				

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 66 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:926234 CAPLUS

DOCUMENT NUMBER: 137:87679

TITLE: Hepatitis C virus: Prospects for future therapies

AUTHOR(S): Wilkinson, Trevor  
CORPORATE SOURCE: Department of Biochemistry, Roche Discovery Welwyn,  
Hertfordshire, AL7 3AY, UK  
SOURCE: Current Opinion in Investigational Drugs (PharmaPress  
Ltd.) (2001), 2(11), 1516-1522  
CODEN: COIDAZ  
PUBLISHER: PharmaPress Ltd.  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English  
TI Hepatitis C virus: Prospects for future therapies  
REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 67 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:763001 CAPLUS

DOCUMENT NUMBER: 135:318715

TITLE: Preparation of macrocyclic NS3-serine  
protease inhibitors of hepatitis C virus  
comprising n-cyclic p2 moieties

INVENTOR(S): Chen, Kevin X.; Arasappan, Ashok; Venkatraman,  
Srikanth; Parekh, Tejal N.; Gu, Haining; Njoroge, F.  
George; Girjavallabhan, Viyyoor M.; Ganguly, Ashit;  
Saksena, Anil; Jao, Edwin; Yao, Nanhua H.; Prongay,  
Andrew J.; Madison, Vincent S.; Vibulbhan, Bancha

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 402 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----	----	-----	-----	-----
-------	------	-------	-------	-------

WO 2001077113	A2	20011018	WO 2001-US10869	20010403
---------------	----	----------	-----------------	----------

WO 2001077113	A3	20020620		
---------------	----	----------	--	--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
CO, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, HR, HU, ID,  
IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG,  
MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ,  
TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU,  
TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG



CA 2405521      AA 20011018    CA 2001-2405521      20010403  
 AU 2001053124    A5 20011023    AU 2001-53124      20010403  
 US 2002107181    A1 20020808    US 2001-825399      20010403  
 US 6846802      B2 20050125  
 EP 1268525      A2 20030102    EP 2001-926601      20010403  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 BR 2001009861    A 20030610    BR 2001-9861      20010403  
 JP 2003530401    T2 20031014    JP 2001-575586      20010403  
 NZ 521455      A 20040625    NZ 2001-521455      20010403  
 ZA 2002007845    A 20040211    ZA 2002-7845      20020930  
 NO 2002004797    A 20021204    NO 2002-4797      20021004  
 PRIORITY APPLN. INFO.:      US 2000-194607P    P 20000405  
    WO 2001-US10869    W 20010403  
 OTHER SOURCE(S):      MARPAT 135:318715  
 TI Preparation of macrocyclic NS3-serine protease inhibitors of  
 hepatitis C virus comprising n-cyclic p2 moieties

L23 ANSWER 68 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER:      2001:320872 CAPLUS  
 DOCUMENT NUMBER:      135:220448  
 TITLE:      Emerging therapies for hepatitis C virus  
    infection  
 AUTHOR(S):      Dymock, Brian W.  
 CORPORATE SOURCE:      Roche Discovery Welwyn, Welwyn Garden City, AL7  
 3AY,  
    UK  
 SOURCE:      Emerging Drugs (2001), 6(1), 13-42  
    CODEN: EMDRFV; ISSN: 1361-9195  
 PUBLISHER:      Ashley Publications Ltd.  
 DOCUMENT TYPE:      Journal; General Review  
 LANGUAGE:      English  
 TI Emerging therapies for hepatitis C virus infection  
 REFERENCE COUNT:      172 THERE ARE 172 CITED REFERENCES  
 AVAILABLE FOR  
    THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
    FORMAT

L23 ANSWER 69 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER:      2000:133728 CAPLUS  
 DOCUMENT NUMBER:      132:175808  
 TITLE:      Hepatitis C inhibitor peptides  
 INVENTOR(S):      Llinas-Brunet, Montse; Bailey, Murray D.; Cameron,  
    Dale; Ghiro, Elise; Goudreau, Nathalie; Poupart,  
    Marc-Andre; Rancourt, Jean; Tsantrizos, Youla S.  
 PATENT ASSIGNEE(S):      Boehringer Ingelheim (Canada) Ltd., Can.

SOURCE: PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000009558	A1	20000224	WO 1999-CA737	19990809
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6767991	B1	20040727	US 1999-368670	19990805
CA 2336597	AA	20000224	CA 1999-2336597	19990809
CA 2336597	C	20060214		
AU 9952732	A1	20000306	AU 1999-52732	19990809
AU 764655	B2	20030828		
BR 9912943	A	20010508	BR 1999-12943	19990809
EP 1105422	A1	20010613	EP 1999-938085	19990809
EP 1105422	B1	20060215		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
TR 200100438	T2	20010621	TR 2001-200100438	19990809
JP 2002522557	T2	20020723	JP 2000-565004	19990809
EE 200100080	A	20020815	EE 2001-80	19990809
NZ 510395	A	20031219	NZ 1999-510395	19990809
TW 577895	B	20040301	TW 1999-88113587	19990809
AT 317854	E	20060315	AT 1999-938085	19990809
NO 2001000604	A	20010205	NO 2001-604	20010205
ZA 2001000972	A	20020718	ZA 2001-972	20010205
BG 105230	A	20011031	BG 2001-105230	20010208
HR 2001000101	A1	20020228	HR 2001-101	20010208
HK 1039947	A1	20050225	HK 2002-101472	20020226
PRIORITY APPLN. INFO.:		US 1998-95945P P 19980810		
		US 1997-55186P P 19970811		
		US 1998-131758 B2 19980810		
		US 1998-219939 B1 19981223		
		WO 1999-CA737 W 19990809		
OTHER SOURCE(S):		MARPAT 132:175808		
TI		Hepatitis C inhibitor peptides		

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 70 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:99946 CAPLUS

DOCUMENT NUMBER: 132:146230

TITLE: Hepatitis C virus-specific T-cell reactivity  
during interferon and ribavirin  
treatment in chronic hepatitis C

AUTHOR(S): Cramp, Matthew E.; Rossol, Siegbert; Chokshi, Shilpa;  
Carucci, Patrizia; Williams, Roger; Naoumov, Nikolai  
V.

CORPORATE SOURCE: Institute of Liver Studies, King's College Hospital,  
London, UK

SOURCE: Gastroenterology (2000), 118(2), 346-355

CODEN: GASTAB; ISSN: 0016-5085

PUBLISHER: W. B. Saunders Co.

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Hepatitis C virus-specific T-cell reactivity during interferon  
and ribavirin treatment in chronic hepatitis  
C

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 71 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:645414 CAPLUS

DOCUMENT NUMBER: 130:199

TITLE: The antiviral compound ribavirin modulates  
the T helper (Th) 1/Th2 subset balance in  
hepatitis B and C virus-specific immune  
responses

AUTHOR(S): Hultgren, Catharina; Milich, David R.; Weiland, Ola;  
Sallberg, Matti

CORPORATE SOURCE: Divisions of Clinical Virology, F 68, Oral  
Microbiology, F 88, and Basic Oral Sciences, F 59,  
Huddinge University Hospital, Huddinge, S-141 86,  
Swed.

SOURCE: Journal of General Virology (1998), 79(10), 2381-2391

CODEN: JGVIAI; ISSN: 0022-1317

PUBLISHER: Society for General Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

TI The antiviral compound ribavirin modulates the T helper (Th)

1/Th2 subset balance in hepatitis B and C virus-specific immune responses

REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 72 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:233225 CAPLUS

DOCUMENT NUMBER: 128:316788

TITLE: Hepatitis B and C viruses: molecular  
identification and targeted antiviral therapies

AUTHOR(S): Berenguer, Marina; Wright, Teresa L.

CORPORATE SOURCE: Department of Veterans Affairs Medical Center,  
University of California, San Francisco, CA, 94121,  
USA

SOURCE: Proceedings of the Association of American Physicians  
(1998), 110(2), 98-112

CODEN: PAAPFD; ISSN: 1081-650X

PUBLISHER: Blackwell Science, Inc.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

TI Hepatitis B and C viruses: molecular identification and targeted  
antiviral therapies

REFERENCE COUNT: 77 THERE ARE 77 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 73 OF 73 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:378498 CAPLUS

DOCUMENT NUMBER: 127:49073

TITLE: Interferon- $\alpha$  treatment induces delayed  
CD4 proliferative responses to the hepatitis  
C virus nonstructural protein 3 regardless of the  
outcome of therapy

AUTHOR(S): Zhang, Zhu-Xu; Milich, David R.; Peterson, Darrell L.;  
Birkett, Ashley; Schvarcz, Robert; Weiland, Ola;  
Sallberg, Matti

CORPORATE SOURCE: Divisions Clinical Virology, Oral Microbiology,  
Infectious Diseases, Huddinge University Hospital,  
Huddinge, Swed.

SOURCE: Journal of Infectious Diseases (1997), 175(6),  
1294-1301

CODEN: JIDIAQ; ISSN: 0022-1899

PUBLISHER: University of Chicago Press

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Interferon-.alpha. treatment induces delayed CD4 proliferative  
responses to the hepatitis C virus nonstructural protein 3  
regardless of the outcome of therapy

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		85.52	251.11

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE
TOTAL	

	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-3.75

FILE 'STNGUIDE' ENTERED AT 11:20:09 ON 01 AUG 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM  
KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Jul 28, 2006 (20060728/UP).